UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 1 of 90 A PHASE 3B, MULTICEN TER, OPEN -LABEL, SIN GLE-ARM 
STUDY TO EVALUATE TH E SAFETY, TOLERABILI TY, AND 
EFFICACY OF ZILUCOPL AN IN PARTICIPANTS W ITH 
GENERALIZED MYASTHEN IA GRAVIS SWITCHING FROM 
INTRAVENOUS COMPLEME NT COMPONENT 5 INHIB ITORS 
TO SUBCUTANEOUS ZILU COPLAN  
 
PROTOCOL MG0017  
PHASE 3 b 
 
SHORT TITLE:  
An open -label study to evaluate the safety, tolerability, and efficacy of subcutaneous zilucoplan 
in participants with generalized myasthenia g ravis who were previously receiving intravenous 
complement component 5 inhibitors  
Sponsor:  
UCB Biopharma SRL  
Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Regulatory agency identifying number:  
IND Number:  134340   
Confidential Material  
Confidential  
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 2 of 90 PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE 
Document History  
Document  Date  Type of amendment  
Amendment 3  30 Nov 2022  Not applicable  
Amendment 2  21 Oct 2022  Not applicable  
Amendment 1  15 Jul 2022  Not applicable  
Original Protocol  24 May 2022  Not applicable  
 
Amendment 3 (3 0 Nov 2022)  
Overall Rationale for the  Amendment:  
The protocol amendment introduces an optional Extension Treatment Period that allows access 
to zilucoplan for participants who wish to continue receiving it after completing the 12 -week 
Main Treatment Period of the study. It allows for study pa rticipants to continue receiving 
zilucoplan treatment until the approval of the marketing application for the indication of 
generalized myasthenia gravis (gMG) in the US or until further notice from the Sponsor.  
The table below does not include correction  of minor typographical errors and 
formatting/stylistic changes.  
Section # and Name  Description of Change  Brief Rationale  
Section 1.1, Synopsis  
Section 3, Table 3 -1 
Objectives and 
estimands/endpoints  
Section 4.1, Overall design  
Section 4.2, Scientific 
rationale for study design  
Section 4.4, End of study 
definition  
Section 6.1, Treatments 
administered  
Section 6.8, Treatment after 
the end of the study  
Section 7.1.2, QTc stopping 
criteria  
Section 8.1.1.6, Patient 
Preference assessment  
Section 8.1.1.8, Time  to 
first receipt of rescue 
therapy  Endpoints updated to define the 
duration. Overall design of the study, 
treatment groups and duration updated 
to include the Extension Treatment 
Period.  To include an Ex tension 
Treatment Period in the study 
and allow eligible 
participants who have 
completed the 12 -week Main 
Treatment Period to have 
continued access to 
zilucoplan.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 3 of 90 Section # and Name  Description of Change  Brief Rationale  
Section 8.1.1.9, Change in 
SOC therapy dose regimen  
Section 1.2, Schema  Figure 1 -1 updated to include the 
Extension Treatment Period.  
Footnotes “d,” “e,” "f," "g," and "h" 
added.  
Footnote “b” modified for clarity 
reasons.  As above.  
Section 1.3, Schedule of 
Activities  Table 1 -2 updated to include the 
Extension Treatment Period and time 
points for data collection.  
Footnote “b,” “c,” “k,” and “u” 
updated.  
Footnote “w”  and “x”  added.  As above.  
 
 
Footnotes “k” and “u” 
modified for clarity reason.  
 
Section 2.3, Benefit/risk 
assessment  Reference to Advisory Committee on 
Immunization Practices added.  Clarification.  
Section 5.1, Inclusion 
criteria  Inclusion Criterion 2 (now 2a) modified 
for clarity reason.  Clarification.  
Inclusion Criteria 7, 8, and 10 (now 7a, 
8a, and 10a, respectively) modified.  Modified to account for the 
Main Treatment Period and 
clarification added on the 
entire study.  
Reference to Advisory Committee on 
Immunization Practices added to 
exclusion criterion 9 (now 9a).  Clarification.  
Section 5.2, Exclusion 
criteria  Exclusion Criteria 3, 12, 14 (now 3a, 
12a, and 14a, respectively) modified.  Modified to account for the 
Main  Treatment Period 
and/or Extension Treatment 
Period.  
Section 6, Study Treatments  Second paragraph modified.  Modified to account for the 
Main Treatment Period and 
the Extension Treatment 
Period for more clarity.  
Section 6.5.1, Permitted 
concomitant treatments 
(medications and therapies)  Modified due to addition of Extension 
Treatment Period to the study.  Modified to account for the 
Main Treatment Period and 
Extension Treatment Period.  
Section 6.5.2, Prohibited 
concomitant treatments 
(medications and  therapies)  The last paragraph modified.  Updated due to the addition 
of the Extension Treatment 
Period to the study.  
Section 6.5.3, Vaccines  Reference to Advisory Committee on 
Immunization Practices added.  Clarification made that 
withdrawal of participant s 
due to prohibited 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 4 of 90 Section # and Name  Description of Change  Brief Rationale  
concomitant medication not 
necessary (except for IV C5 
inhibitors).  
Section 6.5.4, Rescue 
medication  Last paragraph changed.  Clarification.  
Section 7.1, Discontinuation 
of study medication  Paragraph updated.  Clarification.  
Section 7.2, Participant 
discontinuation/withdrawal 
from the study  Criterion 3 updated with general 
prohibited concomitant medication 
being replaced with IV C5 inhibitors.   Clarification.  
Sentence on Early Withdrawal and 
Withdrawal Visits modified.  Updated due to the addition 
of the Extension Treatment 
Period.  
Section 8.3.1, Time period 
and frequency for collecting 
AE and SAE information  Sentence shortened.  Deleted information on the 
Withdrawal and Safety 
Follow -Up Visits as this is 
already given the cross -
referenced Section 4.4.  
Section 8.3.5, Pregnancy  Withdrawal Visit included.  Updated in line with 
modifications made in Table 
1-2. 
Section 8.4, Safety signal 
detection  “(eg, AEs, vital signs, laboratory, or 
ECG results)” deleted.  Updated, since in t he 
Extension Treatment Period 
only a subset of safety 
variables mentioned in the 
deleted parentheses will be 
collected.  
Section 9.7, Planned interim 
analysis and data 
monitoring  Interim analysis was added.  Updated due to the addition 
of the Extension Treatment 
Period.  
Section 10.4, Appendix 4, 
Contraceptive guidance and 
collection of pregnancy 
information  Contraception guidance updated to 
include the whole study rather than just 
the Main Treatment Period.  As above.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 5 of 90 SERIOUS ADVERSE EVEN T REPORTING  
Serious adverse event reporting (24h)  
Fax US and Canada: +1 800 880 6949 or +1 866 890 3175  
Email  Global:  DS_ICT@ucb.com (for interventional clinical studies)  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 6 of 90 TABLE OF CONTENTS  
1 PROTOCOL SUMMARY  ................................ ................................ ...............................  10 
1.1 Synopsis  ................................ ................................ ................................ .......................  10 
1.2 Schema  ................................ ................................ ................................ .........................  15 
1.3 Schedule of Activities  ................................ ................................ ................................ .. 17 
2 INTRODUCTION  ................................ ................................ ................................ ...........  24 
2.1 Study rationale  ................................ ................................ ................................ .............  24 
2.2 Background  ................................ ................................ ................................ ..................  24 
2.3 Benefit/risk assessment  ................................ ................................ ................................  25 
3 OBJECTIVES AND ENDPO INTS  ................................ ................................ .................  26 
3.1 Estimand/intercurrent event handling rationale and impact on the study  ....................  28 
4 STUDY DESIGN  ................................ ................................ ................................ .............  29 
4.1 Overall de sign ................................ ................................ ................................ ..............  29 
4.2 Scientific rationale for study design  ................................ ................................ ............  31 
4.3 Justification for dose  ................................ ................................ ................................ .... 31 
4.4 End of study definition ................................ ................................ ................................ . 32 
5 STUDY POPULATION  ................................ ................................ ................................ .. 33 
5.1 Inclusion criteria  ................................ ................................ ................................ ..........  33 
5.2 Exclusion criteria  ................................ ................................ ................................ .........  34 
5.3 Lifestyle restrictions ................................ ................................ ................................ ..... 36 
5.4 Screen failures  ................................ ................................ ................................ ..............  36 
6 STUDY TREATMENTS  ................................ ................................ ................................ . 36 
6.1 Treatments administered  ................................ ................................ ..............................  36 
6.2 Preparation, handling, storage, and accountability requirements  ................................  38 
6.2.1  Drug accou ntability  ................................ ................................ .............................  38 
6.3 Measures to minimize bias: randomization and blinding  ................................ ............  38 
6.4 Treatment compliance  ................................ ................................ ................................ .. 39 
6.5 Concomitant medication(s)/treatment(s)  ................................ ................................ ..... 39 
6.5.1  Permitted concomitant treatments (medications and therapies)  ..........................  39 
6.5.2  Prohibited concomitant treatments (medications and therapies)  .........................  39 
6.5.3  Vaccines  ................................ ................................ ................................ ...............  40 
6.5.4  Rescue medication  ................................ ................................ ...............................  40 
6.6 Dose modification  ................................ ................................ ................................ ........  41 
6.7 Criteria for study hold or dosing stoppage  ................................ ................................ ... 41 
6.8 Treatment after the end of the study  ................................ ................................ ............  41 
7 DISCONTINUATION OF S TUDY MEDICATION AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ........  42 
7.1 Discontinuation of study medication  ................................ ................................ ...........  42 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 7 of 90 7.1.1  Liver chemistry stopping criteria  ................................ ................................ .........  42 
7.1.2  QTc stopping criteria  ................................ ................................ ...........................  43 
7.2 Participant discontinuation/withdrawal from the study  ................................ ...............  44 
7.3 Lost to follow up  ................................ ................................ ................................ ..........  45 
8 STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...........................  45 
8.1 Efficacy assessments  ................................ ................................ ................................ .... 46 
8.1.1 Clinical efficacy assessments  ................................ ................................ ..............  46 
8.1.1.1  MG-ADL  ................................ ................................ ................................ ... 46 
8.1.1.2  QMG sc ale ................................ ................................ ................................ . 47 
8.1.1.3  MG-QOL15r  ................................ ................................ ..............................  47 
8.1.1.4  Myasthenia Gravis Foundation of America Post -Intervention Status  ....... 47 
8.1.1.5  TSQM -9 ................................ ................................ ................................ ..... 47 
8.1.1.6  Patien t Preference assessment  ................................ ................................ ... 47 
8.1.1.7  Time needed for administration of SC ZLP  ................................ ..............  48 
8.1.1.8  Time to first receipt of rescue therapy  ................................ .......................  48 
8.1.1.9  Change in SOC therapy dose regimen  ................................ ......................  48 
8.1.2  Pharmacodynamics  ................................ ................................ ..............................  48 
8.2 Safety assessments  ................................ ................................ ................................ ....... 48 
8.2.1  Physical examination  ................................ ................................ ...........................  49 
8.2.2  Vital signs  ................................ ................................ ................................ ............  49 
8.2.3  Electrocardiogram  ................................ ................................ ................................  49 
8.2.4  Clinical safety laboratory assessments  ................................ ................................  49 
8.2.5  Suicidal risk monitoring  ................................ ................................ ......................  50 
8.3 AEs and SAEs  ................................ ................................ ................................ ..............  50 
8.3.1  Time period and frequency for collecting AE and SAE information  ..................  50 
8.3.2  Method of detecting AEs and SAEs  ................................ ................................ .... 51 
8.3.3  Follow -up of AEs and SAEs  ................................ ................................ ................  51 
8.3.4  Regulatory reporting requirements for SAEs  ................................ ......................  51 
8.3.5  Pregnancy  ................................ ................................ ................................ ............  51 
8.3.6  Adverse events of special interest  ................................ ................................ ........  52 
8.3.7  Monitoring of infection  ................................ ................................ ........................  52 
8.4 Safety signal detection  ................................ ................................ ................................ . 52 
8.5 Treatment of overdose  ................................ ................................ ................................ . 52 
8.6 Pharmacokinetics  ................................ ................................ ................................ .........  53 
8.7 Immunogenicity assessments  ................................ ................................ .......................  53 
8.8 Health economics  ................................ ................................ ................................ .........  54 
9 STATISTICAL CONSIDER ATIONS  ................................ ................................ .............  54 
9.1 Definition of analysis sets  ................................ ................................ ............................  54 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 8 of 90 9.2 General statistical considerations  ................................ ................................ .................  54 
9.3 Planned efficacy/outcome analyses  ................................ ................................ .............  55 
9.3.1  Secondary efficacy estimand/secondary endpoint analyses  ................................  55 
9.3.2  Other efficacy endpoint analyses  ................................ ................................ .........  55 
9.4 Planned safety and other analyses ................................ ................................ ................  55 
9.4.1  Safety analyses  ................................ ................................ ................................ ..... 55 
9.4.2  Other analyses  ................................ ................................ ................................ ...... 55 
9.5 Handling of protocol deviations ................................ ................................ ...................  55 
9.6 Handling of dropouts or missing data  ................................ ................................ ..........  56 
9.7 Planned interim analysis and data monitoring  ................................ .............................  56 
9.8 Determination of sample size  ................................ ................................ .......................  56 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS ... 57 
10.1  Appendix 1: Regulatory, ethical, and study oversight considerations  .........................  57 
10.1.1  Regulatory and ethical considerations  ................................ ................................ . 57 
10.1.2  Financial disclosure  ................................ ................................ .............................  57 
10.1.3  Informed consent process  ................................ ................................ ....................  58 
10.1.4  Data protection  ................................ ................................ ................................ ..... 58 
10.1.5  Committees structure  ................................ ................................ ...........................  59 
10.1.6  Data quality assurance  ................................ ................................ .........................  59 
10.1.6.1  Case report form completion  ................................ ................................ ..... 59 
10.1.6.2  Apps  ................................ ................................ ................................ ...........  59 
10.1.7  Source documents  ................................ ................................ ................................  60 
10.1.8  Study and site closure  ................................ ................................ ..........................  60 
10.1.9  Publication policy  ................................ ................................ ................................  60 
10.2  Appendix 2: Clinical laboratory tests  ................................ ................................ ..........  62 
10.3  Appendix 3: Adverse events – Definitions and procedures for recording, evaluating, 
follow up, and reporting  ................................ ................................ ...............................  64 
10.4  Appendix 4: Contraceptive guidance and collection of pregnancy information  .........  70 
10.5  Appendix 5: Genetics  ................................ ................................ ................................ ... 73 
10.6  Appendix 6: Liver safety – suggested action s and follow -up assessments  .................  74 
10.7  Appendix 7: Medical device AEs, adverse device effects, SAEs, and device 
deficiencies: Definition and procedures for recording, evaluating, follow -up, and 
reporting  ................................ ................................ ................................ .......................  78 
10.8  Appendix 8: Rapid alert procedures  ................................ ................................ ............  79 
10.9  Appendix 9: Country -specific requirements  ................................ ................................  80 
10.10  Appendix 10: Abbreviations and trademarks  ................................ ..............................  81 
10.11  Appendix 11: Protocol amendment history  ................................ ................................ . 83 
Amendment 1 (15 Jul 2022)  ................................ ................................ ................................ .... 83 
Amendment 2 (21 Oct 2022)  ................................ ................................ ................................ ... 87 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 9 of 90 11 REFERENCES  ................................ ................................ ................................ ................  88 
SPONSOR DECLARATION  ................................ ................................ ................................ .. 90 
 
LIST OF TABLES  
Table  1‒1:  Objectives and estimands/endpoints  ................................ ................................  10 
Table  1‒2:  Schedule of Activities  ................................ ................................ ......................  17 
Table  3‒1:  Objectives and estimands/endpoints  ................................ ................................  26 
Table  6‒1:  Treatment administered  ................................ ................................ ...................  37 
Table  6‒2:  ZLP dose presentations by weight brackets  ................................ .....................  37 
Table  10‒1:  Protocol -required safety laboratory assessments  ................................ .............  62 
Table  10‒2:  Highly effective contraceptive methodsa ................................ .........................  71 
Table  10‒3:  Liver chemistry stopping criteria and follow -up assessments  .........................  74 
Table  10‒4:  Liver chemis try increased monitoring criteria with continued study 
medication  ................................ ................................ ................................ ........  76 
 
LIST OF FIGURES  
Figure  1‒1:  MG001 7 study schematic  ................................ ................................ ................  15 
Figure  7‒1:  Liver chemistry stopping criteria and increased monitoring algorithm  ...........  42 
Figure  7‒2:  Liver chemistry increased monitoring algorithm with continued study 
intervention for participants with ALT 3xULN but <8xULN  .......................  43 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 10 of 90 1 PROTOCOL SUMMARY  
1.1 Synopsis  
Protocol title: A Phase 3b, multicenter, open -label, single -arm study to evaluate the safety, 
tolerability, and efficacy of zilucoplan in participants with generalized myasthenia gravis 
switching from intravenous complement component 5 inhibitors to subcutaneous zilucoplan  
Short title: An open -label study to evaluate the safety, tolerability, and efficacy of subcutaneous 
zilucoplan  in participants with generalized myasthenia gravis  who were previou sly receiving 
intravenous complement component 5 inhibitors  
Rationale:  
Myasthenia gravis (MG) is a serious, sometimes life -threatening, debilitating condition 
associated with numerous symptoms including muscular weakness and fatigue. There remains a 
need f or safe and effective treatments to conveniently treat patients with MG, including 
generalized myasthenia gravis (gMG), where the disease progresses beyond the ocular muscles 
and affects multiple muscle groups throughout the body. Some patients can manage their 
symptoms with oral medications such as an oral acetylcholinesterase inhibitors, corticosteroids, 
or nonsteroidal immunosuppressants. In addition, intravenous immunoglobulin G and plasma 
exchange treatment could be utilized as well. For those whose sy mptoms are not well managed 
by these medications, a potential alternative is long term treatment with approved intravenous 
(IV) complement component 5 (C5) inhibitors (eg, eculizumab or ravulizumab) which have 
proven effective at treating MG symptoms. Howe ver, there remains a need for new therapeutic 
options available to patients for whom IV infusions represent a high administration burden, have 
difficult venous access, or who are in underserved or rural populations where economic access to 
IV infusions is prohibitive. MG0017 aims to evaluate the disease control and safety and 
tolerability after switching from an approved IV C5 inhibitor to subcutaneous (SC) zilucoplan 
(ZLP), as well as the evaluation of patient satisfaction and preference.  
Objectives and en dpoints  
Table  1‒1: Objectives and estimands/endpoints  
Objectives  Estimands/endpoints  
Primary  
To evaluate the safety and 
tolerability of switching from IV 
C5 inhibitors to SC ZLP in study  
participants with gMG  The primary safety endpoints are:  
• Incidence of TEAEs over the Main Treatment Period  
• Incidence of TEAEs leading to withdrawal of study medication  
over the Main Treatment Period  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 11 of 90 Table  1‒1: Objectives and estimands/endpoints  
Objectives  Estimands/endpoints  
Secondary  
To evaluate the efficacy of SC 
ZLP after switching from IV C5 
inhibitors in study  participants 
with gMG  The secondary efficacy estimand is:  
• Treatment: ZLP administered by daily SC injections 
(0.3mg/kg/d ay) 
• Target population: Adult study participants with gMG currently 
receiving an IV C5 inhibitor approved for the treatment of 
gMG according to the protocol -specified inclusion/exclusion 
criteria  
• Endpoint: CFB to Week 12 in MG -ADL score  
• Intercurrent event h andling: The intercurrent events considered 
in this study are:  
− Administration of rescue therapy or changes in SOC dose 
regimens. Data collected at and after the point of the 
intercurrent event will be used as collected to gain 
understanding of clinical pra ctice.  
− Participant discontinuation from the study. It will be 
assumed that the participant had remained on their 
treatment (regardless of rescue therapy administration) 
throughout the study (ie, a "hypothetical strategy" 
assuming participants did not disco ntinue the study and 
remained on treatment).  
• Population level summary: The mean of the endpoint  
To evaluate the efficacy of SC 
ZLP after switching from IV C5 
inhibitors on an additional 
efficacy endpoint in study  
participants with gMG  The secondary efficacy endpoint is:  
• CFB to Week 12 in the QMG score  
This endpoint will be analyzed following the same estimand 
structure as defined for the MG -ADL score. The endpoint assessed 
will change accordingly.  
To evaluate safety and 
tolerability of SC ZLP after 
switching from IV C5 inhibitors 
on additional safety measures in 
study  participants with gMG  The secondary safety endpoints are:  
• Incidence of serious TEAEs over the Main Treatment Period  
• Incidence of study withdrawal over the Main Treatment Period  
Other  
To further explore the efficacy of 
SC ZLP on additional efficacy 
endpoints after switching from 
IV C5 inhibitors in study 
participants with gMG  The other efficacy endpoints are:  
• Time to first receipt of rescue therapy over the Main Treatment 
Period  
• Change in SOC therapy medication dose regimen for gMG 
during the Main Treatment Period  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 12 of 90 Table  1‒1: Objectives and estimands/endpoints  
Objectives  Estimands/endpoints  
• Achievement of Minimal Manifestation Status per MGFA -PIS 
at Week  12 without rescue therapy  
• Achieving MSE, defined as an MG -ADL of 0 or 1 at Week  12 
without rescue therapy  
• CFB t o Week 12 in QMG subscores: ocular, bulbar, 
respiratory, limb  
• CFB to Week 12 in MG -QOL15r score  
• MG-ADL score responder rate (responder is defined as 
achieving ≥3 -point improvement from Baseline [decrease] at 
Week 12 and not having taken rescue therapy)  
• QMG  score responder rate (responder is defined as achieving  
≥5-point improvement from Baseline [decrease] at Week  12 
and not having taken rescue therapy)  
To explore the time needed for 
administration of SC ZLP  The other endpoint is:  
• Time needed for administ ration of SC ZLP  
To explore study participants’ 
treatment satisfaction following 
the use of SC ZLP  The other endpoint is:  
• CFB to Week 12 in TSQM -9 scores  
To explore study participant 
preference following the use of 
SC ZLP  The other endpoint is:  
• Patient P reference assessment at Week 12  
To further evaluate the safety 
and tolerability of SC ZLP after 
switching from IV C5 inhibitors 
on other safety measures in 
study  participants with gMG  The other safety endpoints are:  
• CFBa to Week 12 in clinical laboratory tests  
• CFBa to Week 12 in physical examination  
• ECGa 
• C-SSRS  
• Incidence of TEAEs  
To evaluate the PK of SC ZLP 
after switching from IV C5 
inhibitors  The other PK endpoint is:  
• Plasma concentrations of ZLP and its major metabol ites over 
the Main Treatment Period  
To evaluate the PD of SC ZLP 
after switching from IV C5 
inhibitors  The other PD endpoint is:  
• sRBC lysis assay for evaluation of classical complement 
pathway activation over the Main Treatment Per iod 
a In this study, the clinical laboratory, physical examination, and ECG assessments conducted at Screening will be 
considered the baseline values for evaluating of the other safety endpoints.  
C5=complement component 5; CFB=change from Baseline; C -SSRS=Columbia -Suicide Severity Rating Scale; 
ECG=electrocardiogram; gMG=generalized myasthenia gravis; IV=intravenous; MG -ADL=Myasthenia 
Gravis -Activities of Daily Living; MG -QOL15r=Myasthenia Gravis – Quality of Life revised; 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 13 of 90 Table  1‒1: Objectives and estimands/endpoints  
Objectives  Estimands/endpoints  
MGFA -PIS=Myasthenia Gravis Fo undation of America Post -Intervention Status; MSE=Minimal Symptom 
Expression; PD=pharmacodynamic(s); PK=pharmacokinetic(s); QMG= Quantitative Myasthenia Gravis; 
SC=subcutaneous; SOC=standard of care; sRBC=sheep red blood cell; TEAE=treatment -emergent adver se 
event; TSQM -9=9-item Treatment Satisfaction Questionnaire for Medication; ZLP=zilucoplan  
Overall design  
MG0017 is a Phase 3b, multicenter, open -label, single -arm study to evaluate the safety, 
tolerability, and efficacy of ZLP in adult study participants (≥18 years of age) with gMG 
switching from their current IV C5 inhibitor to SC ZLP. 
To be eligible to participate in this study, participants must be currently receiving an IV C5 
inhibitor approved for the treatment of gMG for at least 3  months (for eculizumab) or 4  months 
(for ravulizumab) prior to Screening (with the last dose being administered at the Screening Visit 
±3 days ), considered to have a clinically stable disease as per the Investigator’s judgment prior to 
Screening , and willing to switch from their current IV C5 inhibitor to SC ZLP.  
The study includes a 2 -week or 8 -week Screening Period (for participants receiving eculizumab 
or ravulizumab, respectively), a 12 -week Main Treatment Period, and an optional Extension 
Treatment Period. A Safety Follow -up (SFU) Visit should be performed 40  days (±7 days) after 
the last dose of study medication.  
The Screening Visit should be scheduled to coincide with the regularly scheduled study 
participant’s IV C5 inhibitor administratio n (±3 days). Up to and including the time of the 
Screening Visit, study participants will continue to receive their IV C5 inhibitor at the 
recommended dose regimen.  
On Day 1, study participants will receive ZLP 0.3mg/kg administered SC. Following in -clinic  
education and training, all study participants will self -inject daily SC doses of study medication 
for the subsequent 12 weeks. Of note, there will be no washout period during the study where 
study participants are not receiving treatment for MG.  
During t he Main Treatment Period, study participants will be contacted via phone call at Week  1, 
Week  4, and Week  8 to assess safety and tolerability. During these phone call visits, the 
Myasthenia Gravis -Activities of Daily Living (MG -ADL) assessment will also be  performed. 
Study participants will return to the clinic at Week  2 and Week  12 to evaluate safety, tolerability, 
and efficacy. Additional assessments will include questionnaires, pharmacokinetics (PK), and 
pharmacodynamics (PD).  
All study participants who complete the 12 -week Main Treatment Period without discontinuing 
study medication will have the option to continue ZLP treatment in the Extension Treatment 
Period after the Week 12 visit. Participants who withdraw during the Main Treatment Period will 
comp lete an Early Withdrawal (EW) Visit followed by a SFU Visit 40 days (±7 days) after the 
last dose of study medication. Participants who opt not to continue into the Extension Treatment 
Period will complete a SFU Visit 40 days (±7 days) after the last dose of study medication.  
The Extension Treatment Period consists of in -clinic visits every 12 weeks (±7  days) and will 
continue until all participants are withdrawn, until ZLP is approved and available in the US, or 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 14 of 90 until further notice from the Sponsor. Durin g these visits, ZLP accountability and resupply will 
be performed, medications updated, and safety will be assessed. Participants who withdraw or 
discontinue ZLP during the Extension Treatment Period will complete a Withdrawal Visit 
followed by a SFU Visit  40 days (±7 days) after the last dose of study medication. Participants 
who transition to commercially available ZLP will complete a Withdrawal Visit but will not 
require a SFU Visit. If by the time a participant completes the Main Treatment Period ZLP is  
commercially available, the participant may transition to commercially available ZLP directly 
following the Week 12 visit at the end of the Main Treatment Period.  
Number of participants  
Twenty study participants are planned to be enrolled in the study.  
Treatment groups and duration  
Study participants will be treated with SC ZLP (0.3mg/kg/day).  
The duration of the study depends on the participant’s decision to continue into the Extension 
Treatment Period and on the commercial availability of ZLP in the US (or until further notice 
from the Sponsor).  
The total duration of the study per participant completing the Main Treatment Period and not 
continuing into the Extension Treatment Period will be approximately 20 to 26 weeks:  
• 2-week Screening Period for study participants receiving eculizumab or an 8 -week Screening 
Period for study participants receiving ravulizumab  
• 12-week Main Treatment Period  
• An SFU Visit 40 days (±7 days) after the last dose of study medication.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 15 of 90 1.2 Schema  
A schematic of the study design is provided in  Figure  1‒1. 
Figure  1‒1: MG0017 study schematic  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BL=Baseline; C5=complement component 5; EW=Early Withdrawal; IV=intravenous; MG -ADL=Myasthenia Gravis -Activities of Daily Living; 
SC=subcutaneous; SFU=Safety Follow -up; ZLP=zilucoplan  
a The Screening Visit should be scheduled to coincide with the regularly scheduled study participant IV C5 inhibitor admi nistration (±3 days).  
b Up to and including the time of the Screening Visit, study participants will continue to receive their IV C5 inhibitor at the  recommended dose regimen. The last 
regularly scheduled IV C5 inhibitor administration must occur at the Sc reening Visit (±3 days) to ensure approximately a 2 -week (eculizumab) or 8 -week 
(ravulizumab) interval between the last regularly scheduled IV C5 inhibitor administration and the first SC ZLP administratio n at the Baseline Visit, 
respectively.  
c At Day 1 o f the Main Treatment Period (BL) in case of no more than a 2 -point change in study participants’ MG -ADL score compared to the Screening Visit 
(±3 days), study participants will switch to SC ZLP (0.3mg/kg/day).  Screening Perioda 
(2-week or 8 -week)  Daily SC ZLP  
until Week 12  
IV C5 inhibitorb Daily SC ZLP  
after Week 12 f Transition to 
commercially available 
Zilucoplan g, h 
(if/when approved in the  
US) 
BL Visit  
Switch, Day 1c Week 12 Visit  
SFU d SFU  Main Treatment Period e 
 Extension Treatment Period  
 
h 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 16 of 90 d For participants who complete the Main Treat ment Period but decide not to continue into the Extension Treatment Period: An SFU Visit will be performed 
40 days (±7 days) after the last dose of study medication.  
e If a study participant permanently withdraws from the study prior to the Week 12 visit, an EW Visit will be performed.  
f For study participants continuing into the Extension Treatment Period, SC ZLP will be provided after completion of the Main T reatment Period until they 
discontinue ZLP, or are able to receive commercial ZLP (if/when availab le in the US), or until further notice from the Sponsor. For participants who 
discontinue ZLP during the Extension Treatment Period, a Withdrawal Visit and a SFU Visit will be conducted 40  days (±7  days) after the last dose of study 
medication.  
g Participa nts who transition to commercially available ZLP (if/when approved in the US) will complete a Withdrawal Visit but will not r equire a SFU Visit.  
h If ZLP is commercially available by the time a participant completes the Main Treatment Period, the particip ant may transition to commercially available ZLP 
directly following the Week 12 visit at the end of the Main Treatment Period.  
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 17 of 90 1.3 Schedule of Activities  
The schedule of study activities is provided in  Table  1‒2. 
Table  1‒2: Schedule of Activities  
Study Period  Screening 
Perioda Main Treatment Period  Extension 
Treatment 
Period  EW/ 
With -
drawal 
Visitb,w 
(In-
clinic)  SFU 
Visit 
(In-
clinic)c Rescue 
Therapy 
Visit (If 
applicable
)d Visit name  Screening 
Visit  
(In-clinic)  Baselinee 
(In-clinic)  Week 1 
(Phone 
call) Week 
2 (In -
clinic)  Week 
4 
(Phone 
call) Week 
8 
(Phone 
call) Week 
12 (In -
clinic)  Week 24, 
36, 48… 
every 12 
weeks  
(In-clinic)  
Visit #  1 2 3 4 5 6 7 8, 9, 10…  – – – 
Day -14 or -56 1 8 15 29 57 84 168, 252, 
336…   (Last 
dose 
+40 
days)   
Visit Windowf ±3d ±2d ±2d ±2d ±2d ±2d ±2d ±7d  ±7d  
Procedure/activity  
Informed consentg X           
Verification of 
inclusion/exclusion criteriag X X          
Study participant safety card 
issued   X          
Demography  X           
Medical/surgical historyh X           
Reason for switch from IV C5 
inhibitor  X           
Height and weighti X      X X X   
Prior and concomitant 
medicationsj X X X X X X X X X X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 18 of 90 Table  1‒2: Schedule of Activities  
Study Period  Screening 
Perioda Main Treatment Period  Extension 
Treatment 
Period  EW/ 
With -
drawal 
Visitb,w 
(In-
clinic)  SFU 
Visit 
(In-
clinic)c Rescue 
Therapy 
Visit (If 
applicable
)d Visit name  Screening 
Visit  
(In-clinic)  Baselinee 
(In-clinic)  Week 1 
(Phone 
call) Week 
2 (In -
clinic)  Week 
4 
(Phone 
call) Week 
8 
(Phone 
call) Week 
12 (In -
clinic)  Week 24, 
36, 48… 
every 12 
weeks  
(In-clinic)  
Visit #  1 2 3 4 5 6 7 8, 9, 10…  – – – 
Day -14 or -56 1 8 15 29 57 84 168, 252, 
336…   (Last 
dose 
+40 
days)   
Visit Windowf ±3d ±2d ±2d ±2d ±2d ±2d ±2d ±7d  ±7d  
Procedure/activity  
Neisseria meningitidis  
vaccinationk X SOC  SOC  SOC  SOC  SOC  SOC  SOC  SOC    
Pregnancy testl X X  X  X X X X X  
Clinical laboratory tests 
(hematology, clinical 
chemistry, and urinalysis)m, n X   X   X  X  X 
Complete physical 
examinationn X      X  X X X 
Vital signs  X X     X  X X X  
12-lead ECGn X   X   X  X X  
Adverse eventso X X X X X X X X X X X 
C-SSRSp X X     X X  X X  
MG-ADLr X X X X X X X  X  X 
QMG scaleq, r  X  X   X  X  X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 19 of 90 Table  1‒2: Schedule of Activities  
Study Period  Screening 
Perioda Main Treatment Period  Extension 
Treatment 
Period  EW/ 
With -
drawal 
Visitb,w 
(In-
clinic)  SFU 
Visit 
(In-
clinic)c Rescue 
Therapy 
Visit (If 
applicable
)d Visit name  Screening 
Visit  
(In-clinic)  Baselinee 
(In-clinic)  Week 1 
(Phone 
call) Week 
2 (In -
clinic)  Week 
4 
(Phone 
call) Week 
8 
(Phone 
call) Week 
12 (In -
clinic)  Week 24, 
36, 48… 
every 12 
weeks  
(In-clinic)  
Visit #  1 2 3 4 5 6 7 8, 9, 10…  – – – 
Day -14 or -56 1 8 15 29 57 84 168, 252, 
336…   (Last 
dose 
+40 
days)   
Visit Windowf ±3d ±2d ±2d ±2d ±2d ±2d ±2d ±7d  ±7d  
Procedure/activity  
MG-QOL15rr  X  X   X  X  X 
MGFA Post -Intervention 
Status        X  X  X 
TSQM -9r  X     X  X    
Patient Preference 
assessmentr       X  X   
Blood sampling for PKs,t    X   X  X  X 
Blood sampling for PDs,t 
(sRBC lysis assay)   X  X   X  X  X 
Last regularly scheduled IV 
C5 inhibitor administrationu X           
SC ZLP dispensedx  X  X    X X    
SC ZLP administrationv  X X X X X X X   X 
Time needed for 
administration of SC ZLP     X   X     
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 20 of 90 Table  1‒2: Schedule of Activities  
Study Period  Screening 
Perioda Main Treatment Period  Extension 
Treatment 
Period  EW/ 
With -
drawal 
Visitb,w 
(In-
clinic)  SFU 
Visit 
(In-
clinic)c Rescue 
Therapy 
Visit (If 
applicable
)d Visit name  Screening 
Visit  
(In-clinic)  Baselinee 
(In-clinic)  Week 1 
(Phone 
call) Week 
2 (In -
clinic)  Week 
4 
(Phone 
call) Week 
8 
(Phone 
call) Week 
12 (In -
clinic)  Week 24, 
36, 48… 
every 12 
weeks  
(In-clinic)  
Visit #  1 2 3 4 5 6 7 8, 9, 10…  – – – 
Day -14 or -56 1 8 15 29 57 84 168, 252, 
336…   (Last 
dose 
+40 
days)   
Visit Windowf ±3d ±2d ±2d ±2d ±2d ±2d ±2d ±7d  ±7d  
Procedure/activity  
Date of first receipt of rescue 
therapy            X 
AChR=acetylcholine receptor; AE=adverse event; ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotra nsferase; 
C5=complement component 5; COVID -19=coronavirus disease 2019; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; EW=Early 
Withdrawal; FDA=Food and Drug Administration; gMG=generalized myasthenia gravis; IV=intravenous; MG=myasthenia gravis; MG -ADL=Myasthenia 
Gravis -Activities of Daily Living; MGFA=Myasthenia Gravis Foundation of A merica; MG -QOL15r=Myasthenia Gravis -Quality of Life Revised; 
PD=pharmacodynamic(s); PLEX=plasma exchange; PK=pharmacokinetic(s); QMG=Quantitative Myasthenia Gravis; SAE=serious adverse e vent; 
SC=subcutaneous(ly); SFU=Safety Follow -up; SOC=standard of care;  sRBC=sheep red blood cell; TSQM -9=9-item Treatment Satisfaction Questionnaire for 
Medication; ZLP=zilucoplan  
a The Screening Visit should be scheduled to coincide with the regularly scheduled study participant IV C5 inhibitor administra tion (±3 days) ( Figure  1‒1). 
b If a study participant permanently w ithdraws from the study prior to the Week 12 visit, the study participant should return to the clinic for an EW Visit as soon  
as possible but no later than the next scheduled visit.  
c Study participants who discontinue ZLP at any point in the study will be  required to return to the clinic for a SFU Visit performed at 40±7 days after their last 
dose to gather additional safety information, including information about on ongoing AEs and the reporting any new SAEs since  the last study visit.  
d For study partic ipants who require rescue therapy (see Section  6.5.4 ), a Rescue Therapy Visit should be conducted prior to the initiation of rescue therapy. If 
the Res cue Therapy Visit coincides with a regularly scheduled study visit, then overlapping study procedures do not need to be dupli cated. The study 
participant will continue ZLP treatment while undergoing rescue therapy if it is considered by the Investigator to  be in his/her best interest.  
e In circumstances where COVID -19 disruptions lead to a study participant being unable to return for Day 1 after 14 or 56 days of the Screening Period, 
respectively, additional days may be included in the Screening Period. Con tact with the Medical Monitor is requested in such situations.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 21 of 90 Table  1‒2: Schedule of Activities  
Study Period  Screening 
Perioda Main Treatment Period  Extension 
Treatment 
Period  EW/ 
With -
drawal 
Visitb,w 
(In-
clinic)  SFU 
Visit 
(In-
clinic)c Rescue 
Therapy 
Visit (If 
applicable
)d Visit name  Screening 
Visit  
(In-clinic)  Baselinee 
(In-clinic)  Week 1 
(Phone 
call) Week 
2 (In -
clinic)  Week 
4 
(Phone 
call) Week 
8 
(Phone 
call) Week 
12 (In -
clinic)  Week 24, 
36, 48… 
every 12 
weeks  
(In-clinic)  
Visit #  1 2 3 4 5 6 7 8, 9, 10…  – – – 
Day -14 or -56 1 8 15 29 57 84 168, 252, 
336…   (Last 
dose 
+40 
days)   
Visit Windowf ±3d ±2d ±2d ±2d ±2d ±2d ±2d ±7d  ±7d  
Procedure/activity  
f The visit windows provided are with respect to the Baseline Visit with the exception of the SFU Visit, in which the visit win dow applies to 40 days after the 
last dose of study medication.  
g Procedures performed as SOC during the Screening Period may be used to determine eligibility. Informed consent must be obtain ed prior to performing any 
study -specific procedures that are not SOC.  
h Screening includes disease history with documented diagnos is of gMG by the MGFA criteria (Class II -IVa) and documented serology for AChR 
autoantibodies.  
i Height will be measured only at Screening.  
j All prescriptions and over -the-counter medications taken during the 30 days prior to Screening through the last study visit will be documented. Note: A 
complete history of medications taken for the treatment of gMG will be collected.  
k To reduce the risk of meningococcal infection ( Neisseria meningitidis ), all study participants must be vaccinated against meningococ cal infections, with at least 
1 dose of quadrivalent meningococcal vaccine and meningococcal serotype B vaccine at least 14 days prior to the first dose of Z LP if not vaccinated within 
3 years prior to the start of study medication. The second dose of the primary vaccination cycle can be administered during the study. Participants who initiate 
study medication less than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylact ic antibiotics (eg, penicillin V 
500mg tw ice daily, third generation cephalosporin) until at least 2 weeks after the initial dose of vaccine(s). The use of fluoroquin olone or macrolide antibiotics 
is not recommended due to the potential for exacerbation of MG. Booster vaccinations should be admin istered in accordance with the most current relevant 
guideline (ie, Advisory Committee on Immunization Practices, United States).  
l For all female study participants of childbearing potential, a negative serum pregnancy test must be documented at Screening . All other pregnancy tests will be 
performed via urine. At the Week 2 Visit, study participants will receive a home pregnancy testing kit with instruction to co mplete the test on the day of the 
Week 8 Visit prior to the conduct of the phone call visit, su ch that the result will be available to report to the site staff during the call.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 22 of 90 Table  1‒2: Schedule of Activities  
Study Period  Screening 
Perioda Main Treatment Period  Extension 
Treatment 
Period  EW/ 
With -
drawal 
Visitb,w 
(In-
clinic)  SFU 
Visit 
(In-
clinic)c Rescue 
Therapy 
Visit (If 
applicable
)d Visit name  Screening 
Visit  
(In-clinic)  Baselinee 
(In-clinic)  Week 1 
(Phone 
call) Week 
2 (In -
clinic)  Week 
4 
(Phone 
call) Week 
8 
(Phone 
call) Week 
12 (In -
clinic)  Week 24, 
36, 48… 
every 12 
weeks  
(In-clinic)  
Visit #  1 2 3 4 5 6 7 8, 9, 10…  – – – 
Day -14 or -56 1 8 15 29 57 84 168, 252, 
336…   (Last 
dose 
+40 
days)   
Visit Windowf ±3d ±2d ±2d ±2d ±2d ±2d ±2d ±7d  ±7d  
Procedure/activity  
m Samples for hematology, clinical chemistry, and urinalysis should be obtained prior to administration of study medication at applicable visits. Clinical 
chemistry tests inc lude AST/serum glutamic -oxaloacetic transaminase, ALT/serum glutamic -pyruvic transaminase, ALP, total and direct bilirubin, amylase, 
and lipase.  
n Clinical laboratory, physical examination, and ECG assessments conducted at Screening will be considered the baseline values for evaluating of the other safety 
endpoints.  
o All AEs and SAEs should be monitored until resolution or stabilization. Serious AEs that occur within 40  days after the last dose of study medication should be 
reported using the procedures ou tlined in Appendix 3 (Section  10.3). 
p In accordance with the draft FDA Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical  Trials Guidance (Food and Drug 
Administration, Guidance for Industry, 2012) study participants will be asked to complete the C -SSRS at study visits as specified.  
q The QMG should be performed at approximately the same time of day prior to dosing (preferab ly in the morning) and administered by the same well -trained 
evaluator (eg, neurologist, physical therapist, or other study staff) at each visit throughout the study.  
r Myasthenia Gravis -Quality of Life Revised , TSQM -9, Patient Preference assessment, QMG, and MG -ADL should be performed prior to dosing and prior to 
any other study procedure s. 
s For local Rescue Therapy Visits only, blood samples for PK and PD analyses will be collected within 1  hour prior to administration of each round of rescue 
therapy. If  a study participant receives PLEX treatment as rescue therapy, PK will be measured in the exchanged plasma. If rescue therapy  is administered at a 
location separate from the clinical site, then there is no need to collect blood samples for PK/PD analyses.  
t Blood samples for PK and PD analyses will be obtained at planned visits prior to dosing (within 1 hour of dosing). Back -up specimens may be retained for 
future exploratory biomarker analyses.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 23 of 90 Table  1‒2: Schedule of Activities  
Study Period  Screening 
Perioda Main Treatment Period  Extension 
Treatment 
Period  EW/ 
With -
drawal 
Visitb,w 
(In-
clinic)  SFU 
Visit 
(In-
clinic)c Rescue 
Therapy 
Visit (If 
applicable
)d Visit name  Screening 
Visit  
(In-clinic)  Baselinee 
(In-clinic)  Week 1 
(Phone 
call) Week 
2 (In -
clinic)  Week 
4 
(Phone 
call) Week 
8 
(Phone 
call) Week 
12 (In -
clinic)  Week 24, 
36, 48… 
every 12 
weeks  
(In-clinic)  
Visit #  1 2 3 4 5 6 7 8, 9, 10…  – – – 
Day -14 or -56 1 8 15 29 57 84 168, 252, 
336…   (Last 
dose 
+40 
days)   
Visit Windowf ±3d ±2d ±2d ±2d ±2d ±2d ±2d ±7d  ±7d  
Procedure/activity  
u Up to and including the time of the Screening Visit, study participants will continue to receive their IV C5 inhibitor at the recommended dose regimen. The last 
regularly scheduled IV C5 inhibitor administration cannot occur beyond the Screening Visit (±3 days) to ensure approximately a 2-week (for eculizumab) or 
8-week (for ravulizumab) interval between the last regularly scheduled IV C5 inhibitor administration and the first SC ZLP admi nistration at the Baseline Visit, 
respectively).  
v Following the first in -clinic administration of ZLP at Baseline and in -clinic education and training, all study participants will self -inject daily SC doses of study 
medication. During the Main Treatment Period, dosing on in -clinic study visit days should be withheld until all assessments have been completed. On days 
when rescue the rapy is concurrently administered, dosing should be withheld until after administration of rescue therapy and PK/PD sampling.  
w Participants who withdraw during the Extension Treatment Period will complete a Withdrawal Visit as soon as possible but no l ater than the next scheduled 
visit. At the Withdrawal Visit, only the following study assessments need to be completed: prior and concomitant medications,  weight, pregnancy testing (for 
women of childbearing potential), C -SSRS, and collection of AEs.  
x At the  Week 12 Visit, ZLP dispensation only occurs for study participants continuing into the Extension Treatment Period . 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 24 of 90 2 INTRODUCTION  
2.1 Study rationale  
Myasthenia gravis is a serious, sometimes life -threatening, debilitating condition associated with 
numerous symptoms including muscular weakness and fatigue. There remains a need for safe 
and effective treatments to conveniently treat patients with MG, inc luding gMG, where the 
disease progresses beyond the ocular muscles and affects multiple muscle groups throughout the 
body. Some patients can manage their symptoms with oral medications such as an oral 
acetylcholinesterase inhibitors, corticosteroids, or no nsteroidal immunosuppressants. In addition, 
intravenous immunoglobulin G (IVIG) and plasma exchange (PLEX) treatment could be utilized 
as well. For those whose symptoms are not well managed by these medications, a potential 
alternative is long term treatme nt with approved IV C5 inhibitors (eg, eculizumab or 
ravulizumab) which have proven effective at treating MG symptoms. However, there remains a 
need for new therapeutic options available to patients for whom IV infusions represent a high 
administration bur den, have difficult venous access, or who are in underserved or rural 
populations where economic access to IV infusions is prohibitive. M G0017 aims to evaluate the 
disease control and safety and tolerability after switching from an approved IV C5 inhibitor  to 
SC ZLP, as well as the evaluation of patient satisfaction and preference.  
2.2 Background  
Myasthenia gravis is a rare complement -mediated autoimmune disease characterized by the 
production of autoantibodies targeting proteins that are critical for the norma l transmission of 
neurotransmitter signals from nerves to muscles. The prevalence of MG in the US and EU is 
estimated at approximately 60,000 and 191,000 cases, respectively. In 15% of patients with MG, 
symptoms remain confined to the ocular muscles. In ap proximately 85% of patients, MG 
progresses beyond the ocular muscles to affect multiple muscle groups throughout the body, a 
condition that is typically referred to as gMG (Gilhus, 2016).  
Patients with gMG present with muscle weakness that characteristical ly becomes more severe 
with repeated use and recovers with rest. Symptoms are typically at their mildest in the morning, 
when overnight inactivity enables replenishment of acetylcholine levels in presynaptic motor 
nerve terminals, and worsen during the cou rse of the day. Muscle weakness can be localized to 
specific muscles, but often progresses to more diffuse muscle weakness (Gilhus, 2016; Gilhus 
and Verschuuren, 2015; Chamanza et al, 2010). Generalized MG symptoms can become 
life-threatening when muscle w eakness involves the diaphragm and intercostal muscles in the 
chest wall that are responsible for breathing. The most dangerous complication of gMG, known 
as myasthenic crisis, requires hospitalization, intubation, and mechanical ventilation. 
Approximately  15% to 20% of patients with gMG will experience a myasthenic crisis within 
2 years of diagnosis (Ramizuddin, 2014).  
Zilucoplan (RA101495) is a 15 -amino acid macrocyclic peptide complement inhibitor designed 
for the treatment of conditions in which inappro priate activation of C5 has been demonstrated to 
play a role. Zilucoplan binds to C5 with high affinity and prevents its cleavage by C5 
convertases into the cleavage products C5a and C5b. Inhibition of C5 cleavage prevents the 
downstream assembly and cytol ytic activity of the membrane attack complex. 
Pharmacologically, ZLP has demonstrated dose -dependent inhibition of C5a and C5b formation 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 25 of 90 following activation of classical or alternative complement pathways, as well as inhibition of red 
blood cell lysis in the serum/plasma from various species.  
Zilucoplan is being investigated in patients with amyotrophic lateral sclerosis and gMG, and also 
other complement -mediated diseases are being considered.  
Inhibition of C5 for the treatment of gMG has already been sho wn to be effective in clinical 
studies with the C5 -blocking antibodies, eculizumab (Howard, 2018; Howard et al, 2013) and 
ravulizumab (Vu et al, 2022), which established that inhibition of the terminal complement 
cascade by blocking cleavage of C5 is a cli nically validated approach for treating gMG. 
However, unlike eculizumab and ravulizumab, ZLP provides patients with the advantages of SC 
self-administration at home.  
The clinical efficacy of ZLP in gMG has been shown in a Phase 2 study, MG0009 (previously 
RA101495 -02.201), and in a Phase 3 study, MG0010 (previously RA101495 -02.301). In 
addition, ZLP has shown a favorable safety and tolerability profile across all completed studies. 
Further detail s are provided in the ZLP Investigator’s Brochure (IB).  
2.3 Benefit/risk assessment  
Zilucoplan is being developed to treat patients with gMG.  
In the Phase 2 study, MG0009, ZLP 0.3mg/kg/day showed a statistically significant and 
clinically meaningful benefit as  measured by improvement on the primary endpoint, the 
Quantitative Myasthenia Gravis (QMG) score, compared to placebo over 12  weeks, as well as on 
the MG -ADL (key secondary endpoint), the Myasthenia Gravis -Quality of Life Revised 
(MG -QOL15r), and the Myast henia Gravis Composite (MGC) score (Howard et al, 2020).  
In the pivotal Phase 3 study, MG0010, a clinically meaningful and statistically significant 
improvement from Baseline in MG -ADL total score at Week 12 (primary endpoint) was 
observed for the ZLP trea tment group (ZLP 0.3mg/kg/day) vs placebo. Significant improvements 
from Baseline in QMG, MGC, and MG -QoL15r scores were also observed at Week 12 for the 
ZLP treatment group vs placebo. Zilucoplan was well tolerated, and no major unexpected safety 
findings  were identified compared to earlier ZLP studies.  
Moreover, in both of these studies, the placebo -corrected clinical efficacy of ZLP 0.3mg/kg/day 
administered SC as measured by the QMG and MG -ADL at Week 12 was numerically superior  
to the efficacy observed  in the Phase  3 study with the approved IV C5 inhibitors eculizumab and 
ravulizumab at Week 26 after treatment initiation with a similar safety and tolerability profile 
(Howard et al, 2017; Vu et al, 2022).  
Given the known increased risk of meningococcal i nfection ( Neisseria meningitidis ) associated 
with inhibition or inherited deficiency of C5, participants who participate in this study with ZLP 
will be required to have documentation of at least 1  dose of N. meningitidis  vaccination at least 
2 weeks prior to study medication administration. In addition, while on treatment with ZLP, 
study participants will be monitored closely for signs and symptoms of N. meningitidis  infection. 
A study participant safety card detailing the signs and symptoms of infection, with instructions to 
seek immediate medical attention if any such symptoms occur, will be provided to each study 
participant. Study participants must be vaccinated w ith at least 1  dose each of quadrivalent 
meningococcal vaccine and meningococcal serotype  B vaccine against N. meningitidis  at least 
14 days before the first administration of SC ZLP if not vaccinated within 3  years prior to the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 26 of 90 start of study medication. The second dose of the primary vaccination cycle can be administered 
during the study.  Booster vaccinations should be administered according to the most current 
relevant guideline (ie, Advisory Committee on Immunization Practices, United States). 
(Section  1.3). 
Given the safety and tolerability profile of ZLP, the efficacy data from the Phase 2 study, 
MG0009, the Phase 3 study, MG0010 , and the efficacy and safety profile of IV C5 inhibitors 
approved for the treatment of gMG, the overall risk to the participants in this study is deemed to 
be low and the benefit -risk balance for study participants is anticipated to be favorable.  
More detailed information a bout the known and expected benefits and risks and reasonably 
expected adverse events (AEs) of ZLP can be found in the IB.  
3 OBJECTIVES AND ENDPO INTS  
Table  3‒1: Objective s and estimands/endpoints  
Objectives  Estimands/endpoints  
Primary  
To evaluate the safety and 
tolerability of switching from IV 
C5 inhibitors to SC ZLP in study  
participants with gMG  The primary safety endpoints are:  
• Incidence of TEAEs over the Main Treatment Period  
• Incidence of TEAEs leading to withdrawal of study medication 
over the Main Treatment Period  
Secondary  
To evaluate the efficacy of SC 
ZLP after switching from IV C5 
inhibitors in study  participants 
with gMG  The secondary efficacy estimand  is: 
• Treatment: ZLP administered by daily SC injections 
(0.3mg/kg/day)  
• Target population: Adult study participants with gMG currently 
receiving an IV C5 inhibitor approved for the treatment of 
gMG according to the protocol -specified inclusion/exclusion 
criteria 
• Endpoint: CFB to Week 12 in MG -ADL score  
• Intercurrent event handling: The intercurrent events considered 
in this study are:  
− Administration of rescue therapy or changes in SOC dose 
regimens. Data collected at and after the point of the 
intercurrent event will be used as collected to gain 
understanding of clinical practice.  
− Participant discontinuation from the study. It will be 
assumed that the participant had remained on their 
treatment (regardless of rescue therapy administration) 
throughout the stu dy (ie, a "hypothetical strategy" 
assuming participants did not discontinue the study and 
remained on treatment).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 27 of 90 Table  3‒1: Objective s and estimands/endpoints  
Objectives  Estimands/endpoints  
• Population level summary: The mean of the endpoint  
To evaluate the efficacy of SC 
ZLP after switching from IV C5 
inhibitors on an additional 
efficacy endpoint in study  
participants with gMG  The secondary efficacy endpoint is:  
• CFB to Week 12 in the QMG score  
This endpoint will be analyzed following the same estimand 
structure as defined for the MG -ADL score. The endpoint assessed 
will change acc ordingly.  
To evaluate safety and 
tolerability of SC ZLP after 
switching from IV C5 inhibitors 
on additional safety measures in 
study  participants with gMG  The secondary safety endpoints are:  
• Incidence of serious TEAEs over the Main Treatment Period  
• Incidence of study withdrawal over the Main Treatment Period  
Other  
To further explore the efficacy of 
SC ZLP on additional efficacy 
endpoints after switching from 
IV C5 inhibitors in study 
participants with gMG  The other efficacy endpoints are:  
• Time to f irst receipt of rescue therapy over the Main Treatment 
Period  
• Change in SOC therapy medication dose regimen for gMG 
during the Main Treatment Period  
• Achievement of Minimal Manifestation Status per MGFA -PIS 
at Week  12 without rescue therapy  
• Achieving MSE, defined as an MG -ADL of 0 or 1 at Week  12 
without rescue therapy  
• CFB to Week 12 in QMG subscores: ocular, bulbar, 
respiratory, limb  
• CFB to Week 12 in MG -QOL15r score  
• MG-ADL score responder rate (responder is defined as 
achieving ≥ 3 -point improvement from Baseline [decrease] at 
Week 12 and not having taken rescue therapy)  
• QMG score responder rate (responder is defined as achieving  
≥5-point improvement from Baseline [decrease] at Week  12 
and not having taken rescue therapy)  
To explore the time needed for 
administration of SC ZLP  The other endpoint is:  
• Time needed for administration of SC ZLP  
To explore study participants’ 
treatment satisfaction following 
the use of SC ZLP  The other endpoint is:  
• CFB to Week 12 in TSQM -9 scores  
To explore study participant 
preference following the use of 
SC ZLP  The other endpoint is:  
• Patient Preference assessment at Week 12  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 28 of 90 Table  3‒1: Objective s and estimands/endpoints  
Objectives  Estimands/endpoints  
To further evaluate the safety 
and tolerability of SC ZLP after 
switching from IV C5 inhibitors 
on other safety measures in 
study  participants with gMG  The other safety endpoints are:  
• CFBa to Week 12 in clinical laboratory tests  
• CFBa to Week 12 in physical examination  
• ECGa 
• C-SSRS  
• Incidence of TEAEs  
To evaluate the PK of SC ZLP 
after switching from IV C5 
inhibitors  The other PK endpoint is:  
• Plasma concentrations of ZLP and its major metabolites over 
the Main Treatment Period  
To evaluate the PD of SC ZLP 
after switching from IV C5 
inhibitors  The other PD endpoint is:  
• sRBC lysis assay for evaluation of classical complement 
pathway activation  over the Main Treatment Period  
a In this study, the clinical laboratory, physical examination, and ECG assessments conducted at Screening will be 
considered the baseline values for evaluating of the other safety endpoints.  
C5=complement component 5; CFB=change from Baseline; C -SSRS=Columbia -Suicide Severity Rating Scale; 
ECG=electrocardiogram; gMG=generalized myasthenia gravis; IV=intravenous; MG -ADL=Myasthenia 
Gravis -Activities of Daily Living; MG -QOL15r=Myasthenia Gravis – Quality of Li fe revised; 
MGFA -PIS=Myasthenia Gravis Foundation of America Post -Intervention Status; MSE=Minimal Symptom 
Expression; PD=pharmacodynamic(s); PK=pharmacokinetic(s); QMG= Quantitative Myasthenia Gravis; 
SC=subcutaneous; SOC=standard of care; sRBC=sheep red blood cell; TEAE=treatment -emergent adverse 
event; TSQM -9=9-item Treatment Satisfaction Questionnaire for Medication; ZLP=zilucoplan  
3.1 Estimand/intercurrent event handling rationale and impact on 
the study  
The estimand corresponding to the efficacy objective to evaluate the efficacy of SC ZLP after 
switching from IV C5 inhibitors in study participants with gMG, is described below:  
• Treatment: ZLP administered by daily SC injections (0.3mg/kg/day).  
• Target popu lation : Adult study participants with gMG currently receiving an IV C5 inhibitor 
approved for the treatment of gMG according to the protocol -specified inclusion/exclusion 
criteria.  
• Endpoint : Change from Baseline (CFB) to Week 12 in MG -ADL score.  
• Intercurre nt event handling : The intercurrent events considered in this study are:  
− Administration of a rescue therapy (Section  6.5.4 ) or changes in standard of c are (SOC) 
dose regimens. Data collected at and after the point of the intercurrent event will be used 
as collected to gain understanding of clinical practice.  
− Participant discontinuation from the study. It is assumed that the participant had remained 
on th eir treatment (regardless of rescue therapy administration) throughout the study (ie, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 29 of 90 a "hypothetical strategy" assuming participants did not discontinue the study and 
remained on treatment).  
• Population -level summary : The mean of the endpoint.  
One of the e fficacy objectives of this Phase 3b study is to evaluate the efficacy of SC ZLP after 
switching from IV C5 inhibitors in study participants with gMG who are willing to switch to SC 
ZLP in a situation which can be common in clinical practice (with the arriv al of new therapeutic 
agents). Thus, the intercurrent event handling strategy to consider data after the use of rescue 
therapy in the analysis and to assume that the study participant had remained on their treatment 
or on rescue therapy after study discont inuation is aligned with the study objective.  
The same estimand structure defined for the MG -ADL score will be used to analyze the endpoint 
of CFB to Week 12 in QMG score.  
4 STUDY DESIGN  
4.1 Overall design  
MG0017 is a Phase 3b, multicenter, open -label, single -arm study to evaluate the safety, 
tolerability, and efficacy of ZLP in study participants with gMG switching from their current IV 
C5 inhibitor to SC ZLP. 
To be eligible to participate in this study, participants must be adults (≥18 years of age) with a 
docu mented diagnosis of gMG (Myasthenia Gravis Foundation of America [MGFA] 
Class  II-IVa), currently receiving an IV C5 inhibitor approved for the treatment of gMG for at 
least 3  months (for eculizumab) or 4  months (for ravulizumab) prior to Screening (with th e last 
dose being administered at the Screening Visit ±3 days) , considered to have a clinically stable 
disease as per the Investigator’s judgment prior to Screening, and willing to switch from their 
current IV C5 inhibitor to SC ZLP. 
The planned enrollment  is 20 study participants in the US.  
The study includes a 2 -week or 8 -week Screening Period (for participants receiving eculizumab 
or ravulizumab, respectively), a 12 -week Main Treatment Period, and an optional Extension 
Treatment Period. A SFU Visit shoul d be performed 40  days (±7 days) after the last dose of 
study medication (Section  6.8, Section  1.2). 
The Screening Visit should be scheduled to coincide with the regularly scheduled study 
participant’s IV C5 inhibitor administration (±3 days). Up to and including the time of the 
Screening Visit, stud y participants will continue to receive their IV C5 inhibitor at the 
recommended dose regimen. The last regularly scheduled IV C5 inhibitor administration cannot 
occur beyond Day  -14 (±3 days) of the Screening Period for study participants receiving 
eculiz umab or beyond Day  -56 (±3 days) of the Screening Period for study participants receiving 
ravulizumab to ensure approximately a 2 -week or 8 -week interval between the last regularly 
scheduled IV C5 inhibitor administration (administered at the Screening Vis it ±3 days) and the 
first SC  ZLP administration at the Baseline Visit, respectively.  
At the end of the Screening Period and in case of no more than a 2 -point change in study 
participants’ MG -ADL score compared to the Screening Visit, study participants wil l enter the 
Main Treatment Period and will switch to SC ZLP (IV C5 inhibitor should not be administered 
after the Screening Visit). On Day 1, study participants will receive ZLP 0.3mg/kg administered 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 30 of 90 SC. Following in -clinic education and training, all stud y participants will self -inject daily SC 
doses of study medication for the subsequent 12 weeks. Single -use pre -filled syringes in 
injection devices will be provided for use during the study.  Of note, there will be no washout 
period during the study where s tudy participants are not receiving treatment for MG.  
During the Main Treatment Period, study participants will be contacted via phone call at Week  1, 
Week  4, and Week  8 to assess safety and tolerability. During these phone call visits, the 
MG-ADL assessme nt will also be performed. Study participants will return to the clinic at 
Week  2 and Week  12 to evaluate safety, tolerability, and efficacy. Additional assessments will 
include questionnaires, PK, and PD. Safety assessments will include AE monitoring, phy sical 
examination, clinical laboratory tests, and Columbia -Suicide Severity Rating Scale (C -SSRS) in 
accordance with the Schedule of Activities (Section  1.3). 
The time needed for preparation and administration of SC ZLP will also be measured during the 
Screening Period and Main Treatment Period in accordance with the Schedule of Activities 
(Section  1.3). 
Study participants are expected to remain on a stable dose regimen of all medications unless 
medically indicated changes become necessary. All SOC therapy medications for gMG should 
be kept at the same dose regimen throughout the Main Treatment Period, including 
corticosteroids and immunosuppressant therapy (IST) drugs. If rescue therapy becomes 
necessary due to major deterioration of a study participant’s clinical status, or risk of MG crisis 
as pe r the Investigator’s judgment, the study participant may receive IVIG or PLEX treatment as 
rescue therapy (Section  6.5.4 ). 
Additionally, if deemed needed as per the Investigator’s judgment, study participant may be 
readministered their previous IV C5 inhibitor or administered a different IV C5 inhibitor after 
discontinuation of the study medication.  
All study participants who complete the 12 -week Mai n Treatment Period without discontinuing 
study medication will have the option to continue ZLP treatment in the Extension Treatment 
Period after the Week 12 visit. Participants who withdraw during the Main Treatment Period will 
complete an EW Visit followe d by a SFU Visit 40  days (±7 days) after the last dose of study 
medication. Participants who opt not to continue into the Extension Treatment Period will 
complete a SFU Visit 40 days (±7 days) after the last dose of study medication.  
The Extension Treatmen t Period consists of in -clinic visits every 12 weeks (±7 days) and will 
continue until all participants are withdrawn, until ZLP is approved and available in the US, or 
until further notice from the Sponsor. During these visits, ZLP accountability and resu pply will 
be performed, medications updated, and safety will be assessed. Participants who withdraw or 
discontinue ZLP during the Extension Treatment Period will complete a Withdrawal Visit 
followed by a SFU Visit 40 days (±7 days) after the last dose of s tudy medication. Participants 
who transition to commercially available ZLP will complete a Withdrawal Visit but will not 
require a SFU Visit. If by the time a participant completes the Main Treatment Period ZLP is 
commercially available, the participant ma y transition to commercially available ZLP directly 
following the Week 12 visit at the end of the Main Treatment Period.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 31 of 90 4.2 Scientific rationale for study design  
The clinical efficacy, safety, and tolerability of ZLP 0.3mg/kg/day administered SC has been 
evaluated over 12 weeks in both MG0009 and MG0010. These studies demonstrated a 
statistically significant and clinically meaningful benefit of ZLP treatment on efficacy measures 
and a favorable safety and tolerability profile over placebo (Section  2.3). MG0017 is an 
open -label, single -arm study to evaluate the safety, tolerability, and efficacy of ZLP in study 
participants with gMG switching from their curr ent IV C5 inhibitor to SC ZLP. The open -label, 
single -arm design without the inclusion of a placebo control is acceptable for this study since SC 
ZLP has already been shown to be numerically superior to the efficacy observed with the 
approved IV C5 inhibit ors eculizumab and ravulizumab (Section  2.3), and it also allows all study 
participants to continue to receive an effective treatment (as opposed to a n inert control). The 
12-week treatment duration of the Main Treatment Period in this study was chosen as it is 
consistent with the pivotal Phase  3 study (MG0010). In the MG0010 study, a rapid separation of 
efficacy between ZLP and placebo was observed aft er 1 week which was maximized within 4 
weeks and was then maintained through the course of the 12 -week study. The rationale for dose 
selection in this study is provided in Section  4.3. The Extension Treatment Period was added to 
provide access to ZLP for participants with gMG who have completed the Main Treatment 
Period  and who wish to continue receiving ZLP.  
The study population will include adults wit h gMG who have been receiving an IV C5 inhibitor 
approved for the treatment of gMG for at least 3 months (for eculizumab) or 4  months (for 
ravulizumab) prior to Screening with a clinically stable disease as per the Investigator’s 
judgment. Only study parti cipants who are willing to switch from their current IV C5 inhibitor to 
SC ZLP will be included in the study. There is no minimum number of study participants 
switching from either eculizumab or ravulizumab in this study in order to keep with real world 
clinical practice for the treatment of patients with gMG.  
4.3 Justification for dose  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 32 of 90 4.4 End of study definition  
Completion of main treatment period for the participant  
A participant is considered to have completed the Main Treatment Period  if he/she c ompleted 
the Week 12 visit and:  
• Decided to enter the Extension Treatment Period . 
OR 
• Transitioned to commercially available ZLP directly after the Week 12 visit (no Withdrawal 
or SFU visit required) . 
OR 
• Decided not to enter the Extension Treatment Period an d completed a SFU visit.  
Completion of study for the participant  
A participant is considered to have completed the study  if he/she completed the Main Treatment 
Period and:  
• Did not enter the Extension Treatment Period . 
OR 
• Entered the Extension Treatment Period and:  
− withdrew from the Extension Treatment Period, discontinued ZLP, and completed the 
Withdrawal and SFU Visits.  
OR 
− transitioned to commercially available ZLP and completed the Withdrawal Visit. No SFU 
Visit is required.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 33 of 90 End of study  
The end of the  study is defined as the date of the last visit of the last participant in the study.  
5 STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1 Inclu sion criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant must be between 18 years and 85 years of age, inclusive, at the time of signing 
the Informed Consent form (ICF).  
Type of participant and disease characteristics  
2a. Participant has been treated with an IV C5 inhibitor approved for the treatment of gMG at the 
recommended dose regimen for at least 3 months (for eculizumab) or 4  months (for 
ravulizumab) prior to Screening with a clinically stable disease as per the Investigator’s 
judgment.  
NOTE: The last dose of the IV C5 inhibitor must be taken at the Screening Visit (±3 days) 
(Section  4.1). Participant is willing to switch from his/her current IV C5 inhibitor to SC ZLP.  
4. Participant has a documented diagnosis of gMG (MGFA Class II -IVa) at Screening based on 
participant history and supported by previous evaluations.  
5. Partic ipant has a well -documented record of positive serology for acetylcholine receptor 
binding autoantibodies prior to Screening.  
6. Participant has no more than a 2 -point change in MG -ADL score at Baseline compared with 
the Screening Visit.  
7a. Participant has h ad no change in corticosteroid dose during the Screening Period and no 
change in corticosteroid dose is anticipated to occur during the 12 -week Main Treatment 
Period.  
8a. Participant has had no change in immunosuppressive therapy, including dose, during th e 
Screening Period and no change in immunosuppressive therapy is anticipated to occur during 
the 12 -week Main Treatment Period.  
9a. Participant has a record of vaccination with at least 1  dose of a quadrivalent meningococcal 
vaccine and meningococcal serot ype B vaccine at least 14  days prior to the first dose of ZLP 
if not vaccinated within 3  years prior to the start of study medication.  
Participants who initiate study medication less than 2 weeks after receiving a meningococcal 
vaccine must receive treatme nt with appropriate prophylactic antibiotics (eg, penicillin V 
500mg twice daily, third generation cephalosporin) until at least 2  weeks after the initial dose 
of vaccine(s). The use of fluoroquinolone or macrolide antibiotics is not recommended due to 
the potential for exacerbation of MG.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 34 of 90 A booster vaccination should also be administered, as clinically indicated, to participants 
who have been previously vaccinated against N. meningitidis in order to be eligible for 
inclusion in this study. Participants als o must agree to receive a booster vaccination during 
the study according to the most current relevant guideline (ie, Advisory Committee on 
Immunization Practices, United States).  
Sex 
10a. Male and/or female  
− A male participant is recommended to agree to use  contraception as detailed in 
Appendix  4 (Section  10.4) of this protocol during the study and for at least 40 days 
(5 half-lives) after the last dos e of study medication, and refrain from donating sperm 
during this period.  
− A female participant is eligible to participate if she is not pregnant (see Appendix  4 
[Section  10.4]), not breastfeeding, and at least one of the following conditions applies:  
◦ Not a woman of childbearing potential (WOCBP) as defined in Appendix  4 
(Section  10.4) 
OR 
A WOCBP who agrees to follow the contraceptive guidance in Appendix  4 
(Section  10.4) during the study and  for at least 40 days (5 half -lives) after the last 
dose of study medication.  
Informed consent  
11. Participant is capable of giving signed informed consent as described in Appendix  1 
(Section  10.1), which includes compliance with the requirements and restrictions listed in the 
ICF and in this protocol.  
5.2 Exclusion criteria  
Participants are excluded from the study if any of the following c riteria apply:  
Medical conditions  
1. Participant has any medical or psychiatric condition that, in the opinion of the Investigator, 
could jeopardize or would compromise the participant’s ability to participate in this study.  
2. Participant has a known hypersensi tivity to any components of the study medication as stated 
in this protocol.  
3a. Participant has had a thymectomy within 6 months prior to Baseline or has one scheduled to 
occur during the 12 -week Main Treatment Period.  
4. Participant has a history of meningo coccal disease.  
5. Participant has or has had a current or recent systemic infection within 2  weeks prior to 
Baseline or an infection requiring IV antibiotics within 4 weeks prior to Baseline.  
6. Participant has active malignancy (except curatively resected squa mous or basal cell 
carcinoma of the skin) requiring surgery, chemotherapy, or radiation within the prior 
12 months (participants with a history of malignancy who have undergone curative resection 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 35 of 90 or otherwise not requiring treatment for at least 12 months prior to Screening with no 
detectable recurrence are allowed).  
7. Participant has a lifetime history of suicide attempt (including an actual attempt, interrupted 
attempt, or aborted attempt), or has had suicidal ideation with at least some intent to act in 
the past 6  months as indicated by a positive response (“Yes”) to either question 4 or question 
5 of the “Screening/Baseline” version of the C -SSRS at Screening.  
8. Participant has alanine transaminase (ALT), aspartate aminotransferase (AST), or alkaline 
phospha tase (ALP) >2.5x upper limit of normal (ULN).  
9. Participant has bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is 
fractionated and direct bilirubin <35%).  
10. Participant has current unstable liver or biliary disease per Investigator assessment defined 
by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or 
gastric varices, persistent jaundice, or cirrhosis.  
NOTE: Stable chronic liver disease (including Gilbert’s syndrome, asymptomatic gallstones, 
and c hronic stable hepatitis B or C) is acceptable if the participant otherwise meets entry 
criteria.  
For study participants with a baseline result >ULN for ALT, AST, ALP, or total bilirubin, a 
baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the electronic case report form (eCRF).  
If a study participant has >ULN ALT, AST, or ALP that does not meet the exclusion limit at 
Screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
clinically relevant increase. In case of a clinically relevant increase, inclusion of the study 
participant must be discussed with the Medical Monitor.  
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeate d 
once for confirmation.  
11. QTc interval >450msec for male participants, QTc >470msec for female participants, or 
QTc >480 msec in participants with bundle branch block.  
NOTE: The QTc is the QT interval corrected for heart rate according to Fridericia's formula 
(QTcF). It is either machine read or manually overread.  
Prior/Concomitant therapy  
12a.Participant has had recent surgery requiring general anesthesia within 2  week s prior to 
Screening or is expected to have surgery requiring general anesthesia during the 12 -week 
Main Treatment Period.  
13. Participant has received a treatment with an experimental drug within 30  days or 5  half-lives 
of the experimental drug (whichever is longer) prior to Baseline.  
14a. Participant has received treatment with rituximab within 6 months prior to Baseline or 
treatment is planned to occur during the study.  
15. Participant has received treatment with IVIG, SC immunoglobulin, or PLEX 4  weeks prior 
to Baseline or participant is on chronic IVIG, SC immunoglobulin, or PLEX.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 36 of 90 Prior/Concurrent clinical study experience  
16. Participant has previously participated in this study or participant has previously been 
assigned to treatment in a study of the medication under investigation in this study.  
17. Participant has participated in another study of an investigational study medication (and/or an 
investigational device) within the previous 30  days or is currently participating in another 
study of an investigational stud y medication (and/or an investigational device).  
Diagnostic assessments  
18. Participant has known positive serology for muscle -specific kinase.  
5.3 Lifestyle restrictions  
There are no lifestyle restrictions during the study.  
5.4 Screen failures  
Screen failures are def ined as study participants who consent to participate in the clinical study 
but are not subsequently entered in the study. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the Co nsolidated 
Standards of Reporting Trials publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demography, screen failure details, eligibility criteria, 
and any serious adverse event (SAE).  
In case of s creen failure, the study participant can be rescreened twice following discussion with 
the UCB Medical Monitor and/or Study Physician.  
6 STUDY TREATMENTS  
Study treatment is defined as an y investigational treatment(s), marketed product(s), placebo , or 
medical device (s) intended to be administered to a study participant according to the study 
protocol.  
Up to and including the time of the Screening Visit, study participants will continue to receive 
their IV C5 inhibitor at the recommended dose regimen . Study treatment (ZLP) will be 
administered during the Main Treatment and Extension Treatment Periods.  
6.1 Treatments administered  
The treatment administered in MG0017 is presented in  Table  6‒1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 37 of 90 Table  6‒1: Treatment administered  
Arm name  Zilucoplan  
Intervention name  Zilucoplan  
Type  Drug  
Dose formulation  Pre-filled syringe  
Unit dose 
strength(s)  16.6mg in 0.416mL  
23.0mg in 0.574mL  
32.4mg in 0.810mL  
Dosage level  0.3mg/kg/day  
Route of 
administration  Subcutaneous injection  
Use Experimental  
IMP  IMP 
Sourcing  Provided centrally by the Sponsor  
Packaging and 
labeling  Study medication will be provided in kits containing 7 prefilled syringes. Each 
syringe and kit will be labeled as required per country requirement.  
Excipients  
Former names  RA101495  
IMP=investigational medicinal product; NIMP=noninvestigational medicinal product  
Zilucoplan 0.3mg/kg/day administered SC is the selected dose for this study. As in other ZLP 
studies, the dose presentation will be selected using the following weight brackets ( Table  6‒2). 
Table  6‒2: ZLP dose presentations by weight brackets  
Minimum (nominal)  
target dose (mg/kg/day)  Actual dose (mg)  Weight range (kg)  Dose range 
(mg/kg/day)  
0.3 16.6 ≥43 to <56  0.30 to 0.39  
0.3 23.0 ≥56 to <77  0.30 to 0.41  
0.3 32.4 ≥77 to 150  0.22 to 0.42  
Study participants who present with a higher body weight (≥150kg) or a lower body weight 
(<43kg) will be accommodated on a case -by-case basis, in consultation with the Medical 
Monitor.  
Study participants will be instructed  to self -inject SC doses daily for the duration of the study. 
The study participant may inject study drug into the abdomen (preferred site), thigh, or upper 
arm. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 38 of 90 6.2 Preparation, handling, storage, and accountability requirements  
The Investigator or designee m ust confirm that appropriate temperature conditions have been 
maintained during transit for all study medication received, and any discrepancies are reported 
and resolved before use of the study medication.  
Only participants enrolled in the study may recei ve study medication and only authorized site 
staff may supply or administer study medication. All study medications must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance 
with the labeled storage cond itions, with access limited to the Investigator and authorized site 
staff.  
The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study medication accountability, reconciliation, and record maintenance 
(ie, receipt, reconciliation, and final disposition records).  
In case an out -of-range temperature is noted, it must be immediately reported as per instructions 
contained in the Investigational Medicinal Product (IMP) Handling Manual.  
The Investigator (or designee) will instruct the study participant to store the study medication 
following the instructions on the label.  
Further guidance and information for the final disposition of unused study medication are 
provided in the IMP Handling Manual.  
6.2.1  Drug account ability  
The eCRF will be used to record study medication dispensing and return information on a 
by-participant basis and will serve as source documentation during the course of the study. 
Details of any study medication lost, damaged (due to breakage or wa stage), not used, partially 
used, disposed of at the study site, or returned to the Sponsor or designee must also be recorded 
on the appropriate forms. All supplies and pharmacy documentation must be made available 
throughout the study for UCB (or designee ) to review.  
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of study medication until returned or destroyed.  
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.  
The Investigator must ensure that the study medication is used only in accordance with the 
protocol.  
Periodically, and/or after completion of the clinical phase of the study, all used (including empt y 
containers/partially used), unused, damaged, and/or expired study medication must be reconciled 
and either destroyed at the site according to local laws, regulations, and UCB standard operating 
procedures (SOPs) or returned to UCB (or designee). Study me dication intended for the study 
cannot be used for any other purpose than that described in this protocol.  
For further details about drug accountability, refer to the IMP Handling Manual.  
6.3 Measures to minimize bias: randomization and blinding  
This is an ope n-label, single -arm study. Therefore, no blinding or randomization is required.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 39 of 90 6.4 Treatment compliance  
At each visit after study medication is dispensed, participants must return sharps containers 
containing used syringes or any expired or defective product.  Drug accountability must be done 
in the study participant’s presence in order to obtain explanations regarding discrepancies in 
compliance with the dosing regimen. Drug accountability must be recorded on the Drug 
Accountability form.  
If a study participant is found to be persistently noncompliant, the Sponsor, in conjunction with 
the Investigator, will make a decision as to whether the participant should be withdrawn from the 
study.  
Study personnel will assess study medication compliance at every  visit to record whether any 
doses were missed.  
If a study participant misses 1 dose (ie, 1 day) of study medication, he/she should take the next 
planned dose as scheduled and the Investigator should be contacted as soon as possible.  
If a study participant  misses 2 or more doses, he/she must notify the Investigator immediately 
and the Medical Monitor should be consulted. Ten or more consecutive missed doses will be 
considered a major protocol deviation.  
6.5 Concomitant medication(s)/treatment(s)  
Concomitant med ications include any prescription or over -the-counter medication that is 
ongoing on Day 1 or that is initiated following the first dose of study medication on Day 1.  
6.5.1  Permitted concomitant treatments (medications and therapies)  
Medications, including over t he counter therapeutics, natural products, and vitamins, should not 
be changed during the study, unless medically necessary.  
Participants are expected to remain on stable dose regimens of SOC therapy for gMG throughout 
the Main Treatment Period, including corticosteroids and IST drugs. If during the Extension 
Treatment Period the Investigator determines that dose reduction of SOC therapy for gMG may 
be a reasonable course of action, dose reduction may be initiated, after contacting the Medical 
Monitor. Stud y participants receiving pyridostigmine treatment may reduce the dose if the 
Investigator identifies intolerable side effects clearly related to pyridostigmine. Prior to altering 
the dose of pyridostigmine, the Investigator should contact the Medical Monit or. Any 
cholinesterase inhibitor, regardless of the dosing regimen, is to be withheld for a minimum of 
10 hours prior to the QMG clinical evaluation (not a requirement for the MG -ADL assessment).  
6.5.2  Prohibited concomitant treatments (medications and therapies ) 
The following concomitant medications are prohibited during the study:  
Absolute contraindications:  
• Aminoglycosides, colomycin, polymyxin, telithromycin, injectable cyclin, macrolides, 
fluoroquinolones  
• Quinines, quinidine, hydroxychloroquine, procainamide  
• Beta-blockers (even in eye drops)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 40 of 90 • Diphenylhydantoin, trimethadione  
• Dantrolene  
• D-penicillamine  
• Magnesium  
Relative contraindications:  
• Curariform agents: use of nondepolarizing molecules of rapid degradation, such as 
atracurium, is possible but requires precise monitoring  
• Benzodiazepines  
• Neuroleptics (phenothiazine)  
• Carbamazepine  
• Lithium  
IV C5 inhibitor must not be administered while the participant is receiving ZLP. If deemed 
needed as per the Investigator’s judgment, study participant may be readministe red their 
previous IV C5 inhibitor or administered a different IV C5 inhibitor after discontinuation of the 
study medication and completion of an EW/Withdrawal Visit. The participant should return for a 
SFU Visit 40 days (±7 days) after the last dose of ZL P. 
6.5.3  Vaccines  
Administration of live and nonlive vaccines is allowed during the study at the discretion of the 
Investigator and should be documented. This includes administration of nonlive coronavirus 
disease 2019 (COVID -19) vaccines authorized at the time of issuance of this protocol. Current 
medical and scientific evidence does not suggest that there is any medical or scientific reason for 
restricting severe acute respiratory syndrome coronavirus 2  vaccinations in ZLP clinical studies.  
Additionally, given the increased risk for N. meningitidis  infection with C5 inhibition or deficit, 
study participants who receive ZLP are required to have documentation of at least 1  dose of 
quadrivalent meningococcal vaccine and meningococcal serotype B vaccine at least 14  days 
prior to the first dose of ZLP if not vaccinated within 3  years prior to the start of study 
medication (Section  5.1). The second dose of the primary vaccination cycle can be administered 
during the study. A booster vaccination should also be administered according to the most 
current relevant guideline (ie,  Advisory Committee on Immunization Practices, United States) to 
study participants who have been previously vaccinated against N. meningitidis.  
6.5.4  Rescue medication  
If rescue therapy becomes necessary due to major deterioration of a study participant’s clini cal 
status or risk of MG crisis, as per the Investigator’s judgment, the study participant may receive 
the following rescue medications:  
• IVIG  
• PLEX  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 41 of 90 If such rescue therapy becomes necessary, the choice of IVIG vs PLEX, as well as the frequency 
and duration o f such therapy, will be determined by the Investigator. Escalation of doses of 
corticosteroids or IST drugs for rescue is not permitted.  
The Sponsor should be notified immediately upon determination that rescue therapy is necessary 
in any given study  participant. A Rescue Therapy Visit should be performed prior to initiation of 
rescue therapy (see Section  1.3 for a list of applicable study procedures).  
If the Investigator, in consultation with the Medical Monitor, considers to be in the best interest 
of the study participant, the study participant will continue ZLP treatment and complete all 
study -specified assessments while undergoing rescue therapy and  through the end of the study. 
The date and time of rescue medication administration, the name and dosage regimen of the 
rescue medication, and the reason for initiation of rescue medication must be recorded.  
6.6 Dose modification  
No dose modifications are all owed during the study.  
6.7 Criteria for study hold or dosing stoppage  
Not applicable for this study given the safety experience of ZLP from clinical studies. Refer to 
the IB for details.  
6.8 Treatment after the end of the study  
At the conclusion of the Main Treatm ent Period, study participants will have the option to 
continue ZLP treatment in the Extension Treatment Period, during which SC ZLP will continue 
to be provided until the approval of the marketing application for the indication of gMG in the 
US or until f urther notice from the Sponsor.  
If at the end of the Main Treatment Period a study participant chooses not to participate in the 
Extension Treatment Period, the participant will complete an SFU Visit 40  days (±7 days) after 
the last dose of study medicatio n and receive SOC treatment off -study, as recommended by the 
treating physician.  
If during the Extension Treatment Period a study participant discontinues ZLP, he/she will 
transition to SOC treatment off -study as recommended by the treating physician. These 
participants will complete a Withdrawal Visit and a SFU Visit 40 days (±7 days) after the last 
dose of study medication.  
If a participant is in the Extension Treatment Period at the time ZLP becomes commercially 
available, he/she will transition to Z LP treatment outside of the study. He/she will complete a 
Withdrawal Visit and will not need to complete a SFU Visit. If by the time a participant 
completes the Main Treatment Period ZLP is commercially available, the participant may 
transition to commerci ally available ZLP directly following the Week 12 visit at the end of the 
Main Treatment Period.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 42 of 90 7 DISCONTINUATION OF S TUDY MEDICATION AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1 Discontinuation of study medication  
Dosing of a study participant must be immediately and permanently discontinued if:  
• Study participant is diagnosed with meningococcal disease  
• In the opinion of the Investigator and/or Sponsor, it is unsafe for the study participant to 
continue dosing with study medication  
• There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test 
In circumstances where permanent discontinuation from study medication may occur, the 
Investigator is to discuss with the study participant the appropriate processes for discontinua tion 
from study medication and further assessments as part of an EW or Withdrawal Visit, followed 
by the SFU Visit. If the study participant does not want to continue the study medication and 
withdraws consent (Section  7.2), the Investigator should contact the Medical Monitor, whenever 
possible, to discuss the withdrawal of a participant in advance.  
7.1.1  Liver chemistry stopping criteria  
Discontinuation of  study medication for abnormal liver function should be considered by the 
Investigator when a study  participant meets one of the conditions outlined in Figure  7‒1 or if the 
Investigator believes that it is in best interest of the participant.  
Study medication will be discontinued immediately and permanently for a participant if liver 
chemistry stopping criteria are met.  
Figure  7‒1: Liver chemistry stopping criteria and increased monitoring algorithm  
 
Continue Study Treatment 
Discontinue Study Treatment Plus 
Bilirubin≥2x
ULN (>35% 
direct ) or plus
INR>1.5, if 
measured*
Possible  
Hy’s LawALT≥3xULNALT
≥8xULNPlus
Symptoms of 
liver injury
or 
hypersensitivityNo
Yes
Yes YesNo No NoSee algorithm 
for continued 
therapy with 
increased liver 
chemistry 
monitoring
Yes
*INR value not applicable to subjects on anticoagulants ALT 
≥3xULN 
but 
<8xULNYes
➢Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
➢Report as an SAE if possible Hy’s Law case: ALT≥3xULN and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5, if measured*Refer to the Liver Safety Required Actions and Follow -up Assessments section in 
Appendix  6. 
Report as an SAE if possible Hy’s Law case: AST/ALT ≥3xULN and Bilirubin 
≥2xULN (>35% direct) or INR>1.5, if measured  
(Note: INR value not applicable to patients on anticoagulants)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 43 of 90 ALT=alanine aminotransferase; AST=aspartate aminotransferase; INR=interna tional normalized ratio; SAE=serious 
adverse event; ULN=upper limit of normal  
Figure  7‒2: Liver chemistry increased monitoring algorithm with continued study 
intervention  for participants with ALT 3xULN but <8xULN  
 
 
ALT=alanine aminotransferase; AST=aspartate aminotransferase; bili=bilirubin; INR=international normalized 
ratio; SAE=serious adverse event; ULN=upper limit of normal  
Specific assessm ents and follow -up actions for potential drug -induced liver injury (PDILI) are 
provided in Appendix 6 (Section  10.6). 
7.1.2  QTc stopping criteria  
If a clini cally significant finding is identified (including, but not limited to changes from 
Baseline in QT interval corrected using Fridericia’s formula [QTcF]) after enrollment, the 
Investigator or qualified designee will determine if the study participant can co ntinue in the study 
and if any change in participant management is needed. This review of the ECG printed at the 
time of collection must be documented. Any new clinically relevant finding should be reported 
as an AE.  
If any of the criteria as listed below based on the ECG reading are met, the ECG will be repeated 
to confirm the finding. In the event that a study participant meets the confirmed criteria, the 
Medical Monitor will be contacted to decide whether the participant will discontinue the study. 
In ca se the decision is to proceed to discontinuation, an EW/Withdrawal Visit will be performed, 
and the study participant will be required to return to the clinic for a SFU Visit 40±7  days after 
their last dose. The study participant should be referred to a sp ecialist (ie, cardiologist) and 
managed as per local guidance.  
• QTc >500msec OR uncorrected QT >600msec  
Continue Study Treatment   and   Monitor Liver Chemistry
Discontinue Study Treatment ALT≥5xULN 
but <8xULN
+ bili <2xULN +
no symptoms
No➢Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
YesALT ≥3xULN 
but <5xULN
+ bili <2xULN  +
no symptomsAble to 
monitor  
weekly 
for  ≥2 
weeksPersists for 
≥2 weeks  
or other 
stopping 
criteria  
met
NoYes Yes
YesNo No
Able to 
monitor  
weekly 
for  ≥4 
weeksPersists for 
≥4 weeks  
or other 
stopping 
criteria  
metNo Yes Yes Yes YesALT ≥5xULN ALT <5xULN 
Yes Yes
*INR value not applicable to subjects on anticoagulants ➢Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
➢Report as an SAE if possible Hy’s Law case: ALT≥3xULN and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5, if measured*Refer to the Liver Safety - Suggested Actions and Follow -up assessments section in 
Appendix  6. 
Report as an SAE if possible Hy’s Law case: AST/ALT ≥3xULN and bilirubin 
≥2xULN (>35% direct) or INR>1.5, if measured  
(Note: INR value not applicable to patients on anticoagulants)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 44 of 90 • Change from Baseline of QTc >60msec  
For study participants with underlying bundle branch block, follow the discontinuation criteria 
listed below:  
Baseline QTc with Bundle Branch Block  Discontinuation QTc Threshold with 
Bundle Branch Block  
<450msec  >500msec  
≥450 to 480msec  ≥530msec  
See the Schedule of Activities (Section  1.3) for data to be collected at the time of treatment 
discontinuation and SFU, and for any further evaluations that need to be completed.  
The study participant should follow the visit schedule as  described in the protocol and the eCRF 
should be completed accordingly.  
7.2 Participant discontinuation/withdrawal from the study  
Study participants are free to withdraw from the study at any time, without prejudice to their 
continued care.  
A study participan t may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or 
administrative reasons.  
If the study participant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.  
If a study participant withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the Investiga tor must document this in the site study records.  
See the Schedule of Activities (Section  1.3) for data to be collected at the time of study 
discontinuation.  
Participants should be withdrawn from the study if any of the following events occur:  
1. Participant develops an illness that would interfere with his/her continued participation.  
2. Participant is noncompliant with the study procedures or medic ations in the opinion of the 
Investigator.  
3. Participant restarts administration of previous IV C5 inhibitor or is administered a different 
IV C5 inhibitor (Section  6.5.2 ). 
4. Participant withdraws his/her consent.  
5. The Sponsor or a regulatory agency requests withdrawal of the participant.  
6. Participant has active suicidal ideation with some intent to act without specific plan, as 
indicated by a positive respons e (“Yes”) to question 4 of the “Since Last Visit” version of the 
C-SSRS. The participant should be referred immediately to a mental healthcare professional 
and may be withdrawn from the study based upon the Investigator’s judgment of benefit/risk 
of contin uing the participant in the study/on study medication.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 45 of 90 7. Participant has active suicidal ideation with a specific plan as indicated by a positive 
response (“Yes”) to question 5 of the “Since Last Visit” version of the C -SSRS. The 
participant should be referr ed immediately to a Mental Healthcare Professional and must be 
withdrawn from the study.  
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a study participant in advance.  
If a study participant withdraws from  the study, the participant will not be replaced.  
If a study participant withdraws from the study, the participant should immediately stop the 
intake of the study medication and will be required to return to the clinic for an EW/Withdrawal 
Visit (depending  on whether the participant withdrew during the Main Treatment Period or 
during the Extension Treatment Period) as soon as possible but no later than the next scheduled 
visit and for a SFU Visit 40±7  days after their last dose of study medication to gather  
information on ongoing AEs and report any new SAEs since the last study visit (Section  1.3). 
7.3 Lost to follow up  
A study  participant  will be considered lost to follow up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions must be taken if a study  participant fails to return to the clinic for a 
required stud y visit:  
• The site must attempt to contact the study  participant and reschedule the missed visit as soon 
as possible, counsel the participant on the importance of maintaining the assigned visit 
schedule, and ascertain whether or not the participant wishes t o and/or should continue in the 
study.  
• Before a study  participant is deemed lost to follow up, the Investigator or designee must 
make every effort to regain contact with the participant (at least 1 phone call and 1 written 
message to the participant), and document his/her effort (date and summary of the phone call 
and copy of the written message in the source documents), to complete the final evaluation . 
All results of these evaluations and observations, together with a narrative description of the 
reason(s ) for removing the study participant, must be recorded in the source documents. The 
eCRF must document the primary reason for withdrawal.  
Should the study  participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study wi th a primary reason of lost to follow up documented in the eCRF.  
8 STUDY ASSESSMENTS AN D PROCEDURES  
Study procedures and their timing are summarized in the Schedule of Activities (Section  1.3). 
Protocol waivers or exemptions are not allowed.  
Immediate safety concerns should be discussed with the Sponsor immediately upon occurrence 
or awareness to determine if the participant should continue or discontinue study medication.  
Adherence to the study design requirements, including those specified in the Schedule of 
Activities (Section  1.3), is essential and required for study conduct.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 46 of 90 All screening evaluations must be completed and reviewed to confirm that potential study  
participants meet all eligibility criteria. The Investigator will maintain a screening log to record 
details of all study  participants screened and to confirm eligibility or record reasons for screening 
failure, as applicable.  
Procedures conducted as part of the study  participant’s routine clinical management (eg, blood 
count)  and obtained before signing of the ICF may be ut ilized for Screening or Baseline purposes 
provided the procedures met the protocol -specified criteria and were performed within the time 
frame defined in the Schedule of Activities (Section  1.3). 
The maximum amount of blood collected from each participant over the duration of the study, 
including any extra assessments that may be required, will not exceed 500mL. Repeat or 
unscheduled samples may be tak en for safety reasons or for technical issues with the samples.  
8.1 Efficacy assessments  
Planned time points for all efficacy assessments are provided in the Schedule of Activities 
(Section  1.3). 
8.1.1  Clinical efficacy assessments  
Clinical evaluators must be adequately trained prior to conducting any efficacy assessments.  
All self -administered patient -reported outcomes (PROs) (MG -QOL15r, 9-item Treatment 
Satisfaction Questionnaire for Medication [ TSQM -9], and Patient Preference assessment) will be 
filled out by the study participant prior to meeting with the physician and prior to dosing or any 
other study procedures. Patient -reported outcomes should be ad ministered in the following order: 
MG-QOL15r, TSQM -9, Patient Preference assessment, and MG -ADL. All remaining clinical 
efficacy assessments should be performed at approximately the same time of day prior to dosing 
(preferably in the morning) and be admini stered by the same well -trained evaluator (eg, 
neurologist, physical therapist, or other study staff experienced in clinical assessments), where 
applicable, in the same order at each visit throughout the study.  
8.1.1.1  MG-ADL 
The MG -ADL is a brief 8 -item interview er-administered PRO designed to evaluate MG 
symptom severity. The MG -ADL targets symptoms and disability across ocular, bulbar, 
respiratory, and axial symptoms. Each item is assessed on a 4 -point scale, where a score of 0 
represents normal function and a s core of 3 represents severely decreased ability to perform that 
function. The total MG -ADL score ranges from 0 to 24, with a higher score indicating more 
disability. A 2 -point change in MG -ADL score is considered clinically meaningful (Muppidi et 
al, 2011;  Wolfe et al, 1999).  
The MG -ADL assessment will be performed at Screening to assess study participant's eligibility 
and at each study visit (either at the site or over the phone) according to the Schedule of 
Activities (Section  1.3). Detailed instructions regarding the administration of the MG -ADL will 
be provided to sites.  
Minimal Symptom Expression, which is designed to assess how many study participa nts become 
free or virtually free of MG symptoms as measured by achieving an MG -ADL total score of 0 or 
1 on therapy (Vissing et al, 2020), will be assessed at Week 12.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 47 of 90 8.1.1.2  QMG scale  
The QMG is a standardized and validated quantitative strength scoring system that was 
developed specifically for MG. If a study participant is receiving a cholinesterase inhibitor, the 
dose must be withheld for at least 10  hours prior to the assessment. The scale tests 13  items, 
including ocular and facial involvement, swallowing, speech, limb strength, and forced vital 
capacity. Higher scores are representative of more severe impairment. Scoring for each item 
ranges from no weakness (0) to severe weakness (3), with an overall score range from 0  to 39. A 
change in the QMG score of 3  points or more may be considered clinically meaningful in a 
typical clinical study population of patients with MG (Katzberg et al, 2014; Barohn et al, 1998).  
8.1.1.3  MG-QOL15r  
The MG -QOL15r is a 15 -item self -administered PRO that was designed to assess quality of  life 
in patients with MG. Each item is scored on a 0 to 2 -point scale (0=Not much at all, 
1=Somewhat, 2=Very much). The total score is the sum of the 15 individual item scores, ranging 
from 0 to 30. Higher scores indicate more severe impact of the disease  on aspects of the patient’s 
life (Burns et al, 2016; Burns et al, 2010).  
8.1.1.4  Myasthenia Gravis Foundation of America Post -Intervention Status  
The Myasthenia Gravis Foundation of America Post -Intervention Status  is a 
physician -determined assessment of clinical  symptoms of MG after initiation of MG -specific 
therapy. Minimal Manifestation is defined as follows:  
“The patient has no symptoms of functional limitations from MG but has some weakness on 
examination of some muscles. This class recognizes that some patie nts who otherwise meet the 
definition of Complete Stable Remission or Pharmacologic Remission do have weakness that is 
only detectable by careful examination.”  
For the purpose of the current study, Minimal Manifestation will be determined at Week  12, the 
EW Visit, or a Rescue Therapy Visit (rather than after 1 year). Change in status (improved, 
unchanged, worse, exacerbation, or died) of MG will also be determined.  
8.1.1.5  TSQM -9 
The TSQM -9 is a self -administered PRO with Likert -type response options that assesses 
satisfaction with medication use over 3 domains: Effectiveness (items 1 through 3), Convenience 
(items 4 through 6), and Global Satisfaction (items 7 through 9). Each domain score ranges from 
0 to 100, with higher scores indicating increased satisfaction. See TSQM user manual version 1.1 
for instructions on calculation of scores. The instrument is not disease specific. The TSQM -9 and 
previous versions have undergone qualitative and psychometric testing and were found to be 
valid and reliable (Regnault et al , 2012; Bharmal et al, 2009; Atkinson et al, 2005; Atkinson et 
al, 2004).  
8.1.1.6  Patient Preference assessment  
The Patient Preference assessment is a self -administered PRO. A single question will be asked at 
the end of the Main Treatment Period and the EW/Withdra wal Visits, assessing the study 
participant’s preference for treatment:  
“Think about your experience of the subcutaneous treatment you received during the clinical trial 
compared with your previous intravenous treatment.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 48 of 90 All things considered, which treatment did you prefer? (please select one answer)  
• Intravenous infusion  
• Subcutaneous injection  
• No preference”  
Given the limitations of the study design, this question/assessment will not produce robust and 
generalizable patient preference data, but it wi ll generate exploratory data into patient 
preferences based on this sample’s experience with the 2 treatments. To generate robust patient 
preference evidence within a clinical study, a cross -over study design is typically used.  
8.1.1.7  Time needed for administration of SC ZLP  
The time it takes for study participants to administer SC ZLP will be recorded (ie, the time it 
takes for the dose to be delivered into the skin/body). The time needed for administration of SC 
ZLP will be assessed by site staff usi ng a stopwatch to record the time needed for study 
participants to complete the administration. Timing using the stopwatch will start at removal of 
the pre -filled syringe needle cap and will stop when the syringe is completely removed from the 
skin.  
8.1.1.8  Time t o first receipt of rescue therapy  
The date of the first receipt of rescue therapy during the 12 -week Main Treatment Period will be 
recorded.  
8.1.1.9  Change in SOC therapy dose regimen  
Any changes to SOC therapy that occur during the study will be recorded.  
8.1.2  Pharmac odynamics  
Blood sampling for PD analysis of complement activation will be performed as specified in the 
Schedule of Activities (Section  1.3). Blood s amples for PD analyses will be obtained prior to 
dosing (within 1 hour of dosing). Instructions for the collection and handling of biological 
samples will be provided by UCB. The actual date and time (24 -hour clock time) of each sample 
will be recorded.  
The sheep red blood cell lysis assay will be used to evaluate classical complement pathway 
activation.  
All back -up samples already planned for collection will be stored for all participants in this study 
to support potential future exploratory biomarker rese arch, which could include, but is not 
limited to the evaluation of biomarkers relative to disease biology and progression, study 
medication treatment and response, and/or mechanism of action of the study medication 
treatment.  
8.2 Safety assessments  
Planned tim e points for all safety assessments are provided in the Schedule of Activities 
(Section  1.3). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 49 of 90 8.2.1  Physical examination  
A complete physical examination wi ll include, at a minimum, abdomen; cardiac; general 
appearance; eyes, ear, nose, and throat; head and neck; musculoskeletal; neurological; 
respiratory; and skin/mucosal. Height and weight will also be measured and recorded. Height 
will only be measured at Screening.  
  
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
Clinically relevant findings or worsening of previous findings will be recorded as AEs.  
8.2.2  Vital signs  
Temperature, pulse rate, respiratory rate, and blood pressure will be assessed.  
Blood pressure and pulse measurements will be assessed in the sitting position with a completely 
automated device. Manual techniques will be used only if an automated device is not available. 
Blood pressure measurements  should preferably be made using the nondominant arm, and the 
same measurement technique should be used throughout the study for the same participants.  
Blood pressure and pulse measurements should be preceded by at least 5  minutes of rest for the 
study  participant in a quiet setting without distractions (eg, television, cell phones).  
8.2.3  Electrocardiogram  
A 12 -lead ECG will be obtained as outlined in the Schedule of Activities (see Section  1.3) using 
an ECG machine that automatically measures the heart rate and measures PR, QRS, QT, and 
QTc intervals. Refer to Section  7 for QTc withdrawal criteria and any additional QTc readings 
that may be necessary.  
All ECG recordings should be taken with the study participant resting in the supine position for 
at least 5 minutes before the recording.  
8.2.4  Clinical safety laboratory assessments  
See Appendix 2 (Section  10.2) for the list of clinical laboratory tests to be performed and the 
Schedule of Activities (Section  1.3) for the timing and frequency.  
The Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the eCRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless judged 
by the Investigator to be more severe than expected for the study participant's condition.  
All labo ratory tests with values considered clinically significantly abnormal during participation 
in the study should be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by the Investigator or Medical Monit or. 
If such values do not return to normal/baseline within a period of time judged reasonable by the 
Investigator, the etiology should be identified, and the Sponsor notified.  
All protocol -required laboratory assessments, as defined in Appendix 2 (Section  10.2), must be 
conducted in accordance with the Laboratory Manual and the Schedule of Activities 
(Section  1.3). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 50 of 90 If laboratory values from nonprotocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are considered 
clinically significant by the Investigator (eg, SAE or AE or dose modification), then the results 
must be recorded in the eCRF.  
8.2.5  Suicidal risk monitoring  
Study participants being treated with ZLP should be monitored appropriately and observed 
closely for sui cidal ideation and behavior or any other unusual changes in behavior.  
Families and caregivers of study participants being treated with ZLP should be instructed to 
monitor participants for the emergence of unusual changes in behavior, as well as the emergen ce 
of suicidal ideation and behavior, and to report such symptoms immediately to the study 
Investigator.  
Suicidality will be assessed by trained study personnel using the C -SSRS (Posner et al, 2011; 
Mundt et al, 2010). The “Screening/Baseline” version of t he C-SSRS will be completed during 
the Screening Visit and the “Since Last Visit” version will be completed at all other time points 
detailed in the Schedule of Activities (Section  1.3). Criteria for participant withdrawal based on 
response to the C -SSRS and Investigator’s judgment are defined in Section  7.2. 
8.3 AEs and SAEs  
The definitions of an AE and SAE can be found in Appendix 3 (Section  10.3). 
Adverse events will be reported by the study  participant (or, when appropriate, by a caregiver, 
surrogate, or the participant's legally authorized representative).  
The Investigator and any d esignees are responsible for detecting, documenting, and recording 
events that meet the definition of an AE or SAE and remain responsible for following up AEs 
that are serious, considered related to the study medication or study procedures, or that caused 
the participant to discontinue the  study medication or the study (see Section  7). 
For results disclosure on public registries (eg, ClinicalTrials.gov ), treatment -emergent adverse 
event s (TEAEs) and treatment -emergent SAEs will be published.  
8.3.1  Time period and frequency for collecting AE and SAE information  
All AEs and SAEs will be collected from the signing of the ICF  until the study participant 
completes  the study (Section  4.4). Collection of AEs and SAEs will be done at the time points 
specified in the Schedule of Activities (Section  1.3). 
In order to ensure complete safety data collection, all AEs occurring during the study (ie,  after 
the signing of the ICF), including any pretre atment and posttreatment periods required by the 
protocol, must be reported in the eCRF even if no study medication was taken but specific study 
procedures were conducted. This includes all AEs not present prior to the Screening Visit and all 
AEs that recu rred or worsened after the Screening Visit.  
All SAEs will be recorded and reported to the Sponsor  or designee within 24 hours, as indicated 
in Appendix 3 (Section  10.3). The Investigator will submit any updated SAE data to the Sponsor 
within 24  hours of it being available.  
The Investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the Investigator is c ertain that they are in no way associated with the study 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 51 of 90 medication), up to 40 days from the end of the study for each participant, and to also inform 
participants of the need to inform the Investigator of any SAE within this period. Serious AEs 
that the I nvestigator thinks may be associated with the study medication must be reported to 
UCB regardless of the time between the event and the end of the study.  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for co mpleting and transmitting SAE reports are provided in Appendix 3 
(Section  10.3). 
8.3.2  Method of detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the study  participant is the preferred method to inquire about 
AE occurrences.  
8.3.3  Follow -up of AEs and SAEs  
After the initial AE/SAE repor t, the Investigator is required to proactively follow each study 
participant at subsequent visits/contacts. All SAEs  and nonserious AEs of special interest (as 
defined in Section  8.3.6 ), will be followed until resolution, stabilization, the Investigator 
determines that it is no longer clinically significant, the event is otherwise explained, or the study 
participant is lost to follow up (as defined in Se ction  7.3). Further information on follow -up 
procedures is given in Appendix 3 (Section  10.3). 
8.3.4  Regulatory reporting requirements for SAEs  
Prompt notification of an SAE by the Investigator to the Sponsor is essential so that legal 
obligations and ethical responsibilities towards the safety of study  participants and the safety of a 
study medication under clinical investigation are met.  
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study medication under clinical investigation. The 
Sponsor will comply with country -specific regulatory requirements re lating to safety reporting to 
the regulatory authority, Institutional Review Boards (IRB) , and Investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions 
according to local regulatory requirements and Spo nsor policy and forwarded to Investigators as 
necessary.  
An Investigator who receives an Investigator safety report describing an SAE or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will review and then file it 
along with the IB and will notify the IRB, if appropriate according to local requirements.  
8.3.5  Pregnancy  
Details of all pregnancies in female study  participants and female partners of male study  
participants who become pregnant will be collected after the start of s tudy medication and until 
40 days after the last dose of study medication.  
If a pregnancy is reported, the Investigator must immediately inform the Sponsor within 
1 working day of learning of the pregnancy and should follow the procedures outlined in 
Appen dix 4 (Section  10.4). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 52 of 90 The participant should discontinue study medication as soon as pregnancy is known (by positive 
pregnancy test), and the followi ng should be completed:  
• The participant should return for an EW/Withdrawal Visit.  
• An SFU Visit should be scheduled 40±7 days  after the participant has discontinued her study 
medication.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, st illbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
8.3.6  Adverse events of special interest  
An AE of special interest is any AE that a regulatory authority has mandated to be reported on an 
expedited basis, regardless of the seriousness, exp ectedness, or relatedness of the AE to the 
administration of a UCB product/compound.  
For ZLP, the following events require immediate reporting (within 24 hours regardless of 
seriousness) to UCB:  
• Hy’s Law  
− Potential Hy’s Law, defined as ≥3x ULN ALT or AST wi th coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the 
biochemical abnormality (ie, without waiting for any additional etiologic investigations 
to have been concluded). Follow -up information should be rep orted if an alternative 
etiology is identified during investigation and monitoring of the study participant.  
8.3.7  Monitoring of infection  
To mitigate the risk of infection, study participants will be counseled and reminded of the early 
signs and symptoms of Neisseria meningitidis  infection. A patient safety card detailing the signs 
and symptoms of infection, with instructions to seek immediate medical attention if any such 
symptoms occur, will be provided to each study participant.  
8.4 Safety signal detection  
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to the study medication so that Investigators, clinical study participants, 
regulatory authorities, and IRBs will be informed appropriatel y and as early as possible.  
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the Patient Safety 
representative.  
As appropriate for the stage of development and accumulated experience with the study 
medication, medically qualified personnel at UCB may identify additional safety measures for 
which data will be periodically reviewed during the study.  
8.5 Treatment of overdose  
For this study, any dose of ZLP greater than the intended daily dose will be considered an 
overdose. Overdose events are only considered AEs or SAEs if there are associated clinical signs 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 53 of 90 and symptoms, or if the act of taking the excess study medication itself is an AE or SAE (eg,  
suicide attempt).  
It is not anticipated that overdose of ZLP will lead to acute or specific systemic TEAEs. In case 
of overdose, clinically appropriate supportive measures should be instituted as determined by the 
clinical scenario and in consultation wit h the Medical Monitor.  
In the event of an overdose, the Investigator  should:  
1. Contact the Medical Monitor immediately.  
2. Closely monitor the study  participant for any AE/SAE and laboratory abnormalities.  
3. Document the quantity of the excess dose as well as the  duration of the overdose in the 
eCRF.  
Decisions regarding dose interruptions or modifications will be made by the Investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the study  participant.  
8.6 Pharmacokinetics  
Blood sampl es of approximately 2mL will be collected for measurement of plasma 
concentrations of ZLP and its major metabolites  as specified in the 
Schedule of Activities (Section  1.3). Blood samples for PK analyses will be obtained prior to 
dosing (within 1 hour of dosing ). Instructions for the collection and handling of biological 
samples will be provided by UCB. The actual date and time (24-hour clock time) of each sample 
will be recorded.  
For local Rescue Therapy Visits only, blood samples for PK analysis will be collected within 
1 hour prior to administration of each round of rescue therapy. If a study participant receives 
PLEX treatmen t as rescue therapy, PK will be measured in the exchanged plasma. If rescue 
therapy is administered at a location separate from the clinical site, then there is no need to 
collect blood samples for PK.  
Samples will be used to evaluate the PK of ZLP and its  metabolites. Samples collected for PK 
analyses of ZLP and metabolite plasma concentration may also be used to evaluate safety or 
efficacy aspects related to concerns arising during or after the study.  
Any changes in the timing or addition of time points f or any planned study assessments must be 
documented and approved by the relevant study team member and then archived in the Sponsor 
and site study files, but will not constitute a protocol amendment. The IRB will be informed of 
any safety issues that requi re alteration of the safety monitoring scheme or amendment of the 
ICF. 
All back -up samples already planned for collection will be stored for all participants in this study 
to support potential future exploratory biomarker research, which could include, but  is not 
limited to the evaluation of biomarkers relative to disease biology and progression, study 
medication treatment and response, and/or mechanism of action of the study medication 
treatment.  
8.7 Immunogenicity assessments  
Immunogenicity is not evaluated i n this study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 54 of 90 8.8 Health economics  
Health economics parameters are not evaluated in this study.  
9 STATISTICAL CONSIDER ATIONS  
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan (SAP).  
9.1 Definition of a nalysis sets  
The following are the defined analysis sets:  
• Enrolled Set (ES): The ES will include all study participants who signed the ICF.  
• Intention -to-Treat (ITT) Population: The ITT Population will include all eligible study 
participants. Efficacy analy ses will be performed on the ITT in case there is a difference of at 
least 5 participants as compared to the modified Intention -to-Treat (mITT) Population.  
• Modified ITT Population: The mITT Population will include all eligible study participants 
who receiv ed at least 1 post -Baseline dose of study medication and had at least 
1 post-Baseline assessment. The mITT Population will be used for all efficacy analyses.  
• Safety Set (SS): The SS will include all study participants who received at least 1  dose of 
study medication and will be used for the demography and safety analyses.  
• Pharmacokinetic Per -Protocol Set (PK -PPS): The PK -PPS will include all study participants 
in the safety population who received at least 1 dose of study medication and had at least 
1 quant ifiable PK measurement postdose of study medication without important protocol 
deviations that would affect the PK. The PK -PPS will be used for all PK analyses.  
• Pharmacodynamic Per -Protocol Set (PD -PPS): The PD -PPS will include all study 
participants in th e safety population who received at least 1 dose of study medication and had 
at least 1  quantifiable PD measurement postdose of study medication without important 
protocol deviations that would affect the PD. The PD -PPS will be used for all PD analyses.  
Additional detail about analysis sets will be provided in the SAP.  
9.2 General statistical considerations  
Statistical analysis and generation of tables, figures, and study participant data listings will be 
performed using statistical analysis system (SAS®, SAS Institute, Cary, NC, US) Version 9.4 or 
higher using validated program code according to relevant SOP.  
For continuous parameters, descriptive statistics will include the number of study participants, 
arithmetic mean, standard deviation (SD), median, minimu m, and maximum (with 25th and 75th 
percentiles as optional). For categorical parameters, the number and percentage of study 
participants in each category will be presented.  
For ZLP plasma concentration, the geometric mean and corresponding coefficient of variation 
(CV) will be presented.  
Baseline is defined as the last nonmissing measurement collected before the first injection.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 55 of 90 9.3 Planned efficacy/outcome analyses  
9.3.1  Secondary efficacy e stimand/secondary endpoint analyses  
For the efficacy endpoint, CFB to Week 12 in MG -ADL score, a one -sample t -test will be used 
to compare the mean CFB to Week 12 in MG -ADL score to a noninferiority (NI) margin. The NI 
margin being investigated is a clinic ally relevant 2 -point increase (worsening) at Week 12. The 
Week  12 CFB will be compared to 2 at a 1 -sided α=0.025 level for the mITT Population.  
Additional supplementary analyses and sensitivity analyses for the secondary efficacy estimand 
will be provided  in the SAP.  
The additional secondary efficacy endpoint (CFB to Week 12 in QMG score) will be analyzed 
following the estimand structure defined for the MG -ADL score (Section  3.1). These analyses 
will be descriptive.  
9.3.2  Other efficacy endpoint analyses  
The other efficacy endpoints analyses will be descriptive. Additional information about these 
analyses will be provided in the SAP.  
9.4 Planned safety and other analyses  
9.4.1  Safety analyses  
Safety analyses will be performed on the Safety Set.  
Adverse events will be coded using the Medical Dictionary for Regulatory Activities. A TEAE is 
defined as any event that was not present prior to the first administration of stud y medication or 
any unresolved event already present before the first administration of study medication that 
worsens in intensity following exposure to treatment. Incidence rates for TEAEs will be 
summarized overall, by maximum severity, and by relationsh ip to study medication. Serious AEs 
will also be summarized.  
Laboratory evaluations, physical examinations, and ECG will be presented in listings and 
summarized over time. In this study, the clinical laboratory, physical examination, and ECG 
assessments co nducted at Screening will be considered the baseline values for evaluating of the 
other safety endpoints.  
A by -participant listing of the C -SSRS questionnaire data will be provided.  
9.4.2  Other analyses  
Individual PK results will be presented in listings and sum marized using descriptive statistics.  
Pharmacodynamic endpoints will be presented in listings and summarized at each scheduled 
assessment time point.  
9.5 Handling of protocol deviations  
Important protocol deviations are deviations from the protocol which could  potentially have a 
meaningful impact on study conduct or on the key safety, efficacy, or other outcomes for an 
individual study participant. The criteria for identifying important protocol deviations and the 
classification of important protocol deviations  will be defined within the Important Protocol 
Deviations Template. To the extent feasible, rules for identifying protocol deviations will be 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 56 of 90 defined without review of the data and without consideration of the frequency of occurrence of 
such deviations. Wh enever possible, criteria for identifying important protocol deviations will be 
implemented algorithmically to ensure consistency in the classification of important protocol 
deviations across all study participants.  
All important protocol deviations will b e listed by study participant.  
A listing of all important protocol deviations related to the COVID -19 pandemic will be 
provided. Additionally, this listing will be repeated by during and post - the COVID -19 pandemic 
(in case the pandemic ends before the stu dy is complete) based on the deviation start dates 
relative to the pandemic cutoff dates.  
9.6 Handling of dropouts or missing data  
For secondary efficacy analyses, missing data will be handled according to the secondary 
efficacy estimand definition:  
• For missing data of participants who discontinue from the study, a missing at random 
assumption will be used for imputation. This is in relation to the assumption that the 
participant had remained on their treatment throughout the study.  
• For other missing data , the same missing at random assumption as the one used for imputing 
missing data of participants who discontinue from the study will be applied.  
Missing or partial dates for safety evaluations will be imputed and full details of these algorithms 
will be p resented in the SAP. Baseline is defined as the last nonmissing pretreatment 
measurement (Section  9.2). Therefore, data from the Screening Visit (if a vailable) will be used 
as Baseline values if data are missing at Day 1.  
No further imputations of any other missing data are planned.  
9.7 Planned interim analysis and data monitoring  
If ZLP is not commercially available in the US at the time of the last visit of the last participant 
in the Main Treatment Period, an interim analysis will be conducted. This interim analysis will 
include all data collected during the Main Treatment Period.  
9.8 Determination of sample size  
The secondary efficacy estimand will investiga te if the Week 12 MG -ADL score is noninferior 
to the Baseline MG -ADL score with an NI margin of 2. It is assumed that the Week  12 CFB has 
an SD of 3 and that the true CFB is 0. Given a sample size of 20 study participants, the study has 
approximately 80% p ower to detect this, based on a 1 -sided alpha of 0.025.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 57 of 90 10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
10.1 Appendix 1: Regulatory, ethical, and study oversight 
considerations  
10.1.1  Regulatory and ethical considerations  
The study will be conducted under the auspices of an IRB, as defined in local regulations, 
International Council for Harmonisation (ICH) -Good Clinical Practice (GCP), and in accordance 
with the ethical principles that have their origin in the Declaration of Helsinki.  
The Investigator/UCB will ensure that an appropriately constituted IRB that complies with the 
requirements of the current ICH -GCP version or applicable country -specific regulations will be 
responsible for the initial and continuing review and approval of the clinical study. Prior t o 
initiation of the study, the Investigator/UCB will forward copies of the protocol, ICF, IB, 
Investigator’s curriculum vitae (if applicable), advertisement (if applicable), and all other 
participant -related documents to be used for the study to the IRB fo r its review and approval.  
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB for the protocol.  
The Investigator will also promptly report to the IRB all changes in the study, all unanticipated 
problems involving risks to study participants or others, and any protocol deviations, to eliminate 
immediate hazards to study participants.  
The Investigator will not make any changes in the study or study conduct without IRB approval, 
except where necessary  to eliminate apparent immediate hazards to the study participants. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the Investigator to obtain an expedited review by the IRB as 
allowed.  
As part of the IRB requirements for continuing review of approved studies, the Investigator will 
be responsible for submitting periodic progress reports to the IRB (based on IRB requirements), 
at intervals appropriate to the degree of study partic ipant risk involved, but no less than once per 
year. The Investigator should provide a final report to the IRB following study completion.  
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all act ive Investigators in accordance with applicable regulatory requirements. 
The appropriate IRB will also be informed by the Investigator or the Sponsor, as specified by the 
applicable regulatory requirements. Where applicable, Investigators are to provide th e Sponsor 
(or its representative) with evidence of such IRB notification.  
10.1.2  Financial disclosure  
Insurance coverage will be handled according to local requirements.  
Finance and insurance are addressed in the Investigator and/or contract research organization  
agreements, as applicable.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 58 of 90 10.1.3  Informed consent process  
Study participant’s informed consent must be obtained and documented in accordance with local 
regulations, ICH -GCP requirements, and the ethical principles that have their origin in the 
principles of the  Declaration of Helsinki.  
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the study participant in both oral and written form by the 
Investigator (or designee). Each participant will have the opportunity to discuss the study and its 
alternatives with the Investigator.  
Prior to participation in the study, the ICF should be signed and personally dated by the study 
participant, or his/her legal representative, and by the person who c onducted the informed 
consent discussion (Investigator or designee). The study participant or his/her legal 
representative must receive a copy of the signed and dated ICF. As part of the consent process, 
each study participant must consent to direct access  to his/her medical records for study -related 
monitoring, auditing, IRB review, and regulatory inspection.  
If the ICF is amended during the study, the Investigator (or the Sponsor, if applicable) must 
follow all applicable regulatory requirements pertainin g to the approval of the amended ICF by 
the IRB and use of the amended form.  
All studies conducted at centers in the US must include the use of a Health Insurance Portability 
and Accountability Act authorization form.  
The participant may withdraw his/her c onsent to participate in the study at any time. A 
participant is considered as enrolled in the study when he/she has signed the ICF. An eCRF must 
not be started, nor may any study specific procedure be performed for a given participant, 
without having obta ined his/her written consent to participate in the study.  
10.1.4  Data protection  
UCB staff (or designee) will affirm and uphold the study participant’s confidentiality. 
Throughout this study, all data forwarded to UCB (or designee) will be identified only by the 
participant number assigned at Screening.  
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB, or representatives of regulatory authorities will be allowed to review that portion of the 
participant’s prima ry medical records that directly concerns this study (including, but not limited 
to, laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a participant’s study participation, and autopsy report s for deaths 
occurring during the study).  
The study participant must be informed that his/her personal study -related data will be used by 
the Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the study participant.  
The study participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by 
appropriate IRB members, and by inspectors from regulatory authorities.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 59 of 90 10.1.5  Committees structure  
Not applicable.  
10.1.6  Data quality assurance  
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The Invest igator is 
responsible for verifying that data entries are accurate and correct by physically or electronically 
signing the CRF.  
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  
The Inves tigator must permit study -related monitoring, audits, IRB review, and regulatory 
agency inspections and provide direct access to source data documents.  
The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data.  
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by authorized site personnel are accurate, legible, contemporaneous, original, and 
attributable from source documents; that the safety and rights of study participants are being 
protected; and that the study is being conducted in accordance with the currently approved 
protocol and any other study agreements, ICH -GCP, and all applicable regulatory requirements.  
All essential documents must be retained by the Investigator for the minimum retention period 
mandatory under the applicable local laws and regulations. The Investigator will contact UCB 
for authorization prior to the destruction of any study records or in the event of accidental loss or  
destruction of any study records. The Investigator will also notify UCB should he/she relocate or 
move the study -related files to a location other than that specified in the Sponsor’s trial master 
file. 
Quality tolerance limits will be established for the  study using parameters related to patient 
safety reporting and reliability of study results. The parameters will be monitored throughout the 
study to identify systematic issues. Parameters used, parameter values, important deviations from 
the quality tole rance limits, and actions taken will be summarized in the clinical study report.  
10.1.6.1  Case report form completion  
The Investigator is responsible for prompt reporting of accurate, complete, and legible data in the 
eCRFs and in all required reports.  
Any change o r correction to the eCRF after saving must be accompanied by a reason for the 
change.  
Corrections made after the Investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the Investigator.  
The Investigator shoul d maintain a list of personnel authorized to enter data into the eCRF.  
Detailed instructions will be provided in the eCRF Completion Guidelines.  
10.1.6.2  Apps  
Not applicable.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 60 of 90 10.1.7  Source documents  
All source documents must be accurate, clear, unambiguous, permanent, and  capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self -stick notes). Photocopies and /or printouts of eCRFs are not considered 
acceptable source documents.  
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x -rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, quality of life 
questionnaires, or video, for example. Source documents should be kept in a secure, limited 
access area.  
Source documents that are computer generated and s tored electronically must be printed for 
review by the monitor (eg,  ECG reports). Once printed, these copies should be signed and dated 
by the Investigator and become a permanent part of the study participant’s source documents. 
The Investigator will facil itate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.  
Electronic data records, such as Holter monitor records or electroencephalogram records, must 
be saved and stored as instructed by UCB (or designee).  
10.1.8  Study and site closure  
The Sponsor designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of the Sponsor. Study sites will be closed upon s tudy 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The Investigator may initiate study -site closure at any time, provided there is reasona ble cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the Sponsor or Investigator may include but are 
not limited to:  
• Failure of the Investigator to comply with the protocol, the requirements of the IRB or local 
health authorities, the Sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of study participants by the Investigator  
• Discontinuation of further study medication development  
10.1.9  Publication policy  
The results of this  study may be published or presented at scientific meetings. If this is foreseen, 
the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. 
This allows the Sponsor to protect proprietary information and to provide com ments.  
The Sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the Sponsor will generally support publication of 
multicenter studies only in their entirety and not as indiv idual site data. In this case, a 
coordinating Investigator will be designated by mutual agreement.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 61 of 90 Authorship will be determined by mutual agreement and in line with International Committee of 
Medical Journal Editors authorship requirements.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 62 of 90 10.2 Appendix 2: Cl inical laboratory tests  
The tests detailed in the table below will be performed by the central laboratory.  
• Local laboratory results are only required in the event that the central laboratory results are 
not available in time for either study medication adm inistration and/or response evaluation. If 
a local sample is required, it is important that the sample for central analysis is obtained at 
the same time.  Additionally, if the local laboratory results are used to make either a study 
medication decision or r esponse evaluation, the results must be entered into the eCRF.  
• The use of local laboratory results may be considered, if necessary, after consultation with 
the appropriate Sponsor representative (eg, Clinical Project Manager or Study Physician).  
• Protocol -specific requirements for inclusion or exclusion of study  participants are detailed in 
Section  5.1 and Section  5.2 of the protocol.  
• Additional tests may be performed at any time during the study as determined necessary by 
the Investigator or required by local regulations.  
Table  10‒1: Protocol -required safety laboratory assessments  
Laboratory 
assessme nts Parameters  
Hematology  Platelet count  RBC indices : 
MCV  
MCH  
%Reticulocytes  WBC count with 
differential : 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  RBC count  
Hemoglobin  
Hematocrit  
Clinical 
chemistry a BUN  Potassium  AST/SGOT  Total and direct 
bilirubin  
 Creatinine  Sodium  ALT/SGPT  Total protein  
 Glucose  Calcium  Alkaline phosphatase  Amylase  
 Lipase   
Routine 
urinalysis  • Specific gravity  
• pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte 
esterase by dipstick  
• Microscopic examination (if blood or protein is abnormal)  
Other screening 
tests • Follicle -stimulating hormone and estradiol (as needed in women of 
non-childbearing potential only)  
• Serum hCG pregnancy test (as needed for women of childbearing potential) b 
The results of each test must be entered into the eCRF.  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; eCRF=electronic 
Case Report form; HBsAg=hepatitis B surface antigen; hCG=human chorionic gonadotrop in; 
INR=international normalized ratio; IRB=Institutional Review Board; MCH=mean corpuscular hemoglobin; 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 63 of 90 Table  10‒1: Protocol -required safety laboratory assessments  
Laboratory 
assessme nts Parameters  
MCV=mean corpuscular volume; RBC=red blood cell; SAE=serious adverse event; SGOT=serum glutamic -
oxaloacetic transaminase; SGPT=serum glutamic -pyruvic t ransaminase; ULN=upper limit of normal; 
WBC=white blood cell  
a Details of liver chemistry stopping criteria and required actions and follow -up assessments after liver stopping 
or monitoring event are given in Section  7.1.1  and Appendix 6 (Section  10.6). All events of ALT ≥3×ULN and 
bilirubin ≥2×ULN (> 35% direct bilirubin) or ALT ≥3×ULN and INR >1.5, if INR measured, may indicate 
severe liver injury (possible Hy’s Law) and must be reported as an SAE (excluding studies of hepatic 
impairment or cirrhosis).  
b Local urine pregnancy testing will be performed  at visits subsequent to the Screening Visit.  
Investigators must document their review of each laboratory safety report.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 64 of 90 10.3 Appendix 3: Adverse events – Definitions and procedures for 
recording, evaluating, follow up, and reporting  
Definition of AE  
AE definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, temporally 
associated with the use of study medication, whether or not considered related to the study 
medication.  
• NOTE: An AE can therefore be any unfavorable  and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of study medication.  
 
Events meeting  the AE definition  
• Any abnormal laboratory test results (hematology, clinical  chemistry, or urinalysis) or other 
safety assessments (eg, ECG, radiological scans, vital signs measurements), including those 
that worsen from Baseline, considered clinically significant in the medical and scientific 
judgment of the Investigator (ie, not  related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition, including either an increase in 
frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study medication admin istration even though it 
may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study medication or 
a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/self -harming intent. Such overdoses should be 
reported regardless of sequelae.  
• “Lack of efficacy” or “failure of exp ected pharmacological action” per se will not be reported 
as an AE or SAE. Such instances will be captured in the efficacy assessments. However, the 
signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as an 
AE or SAE if they fulfil the definition of an AE or SAE.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 65 of 90 Events NOT  meeting the AE definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments 
which are associated with the underlying disease, unless judged by the Investigator to be more 
severe than expected for the study  participant’s condition.  
• The dise ase/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the study participant’s 
condition.  
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition  that leads to the 
procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospital).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected  at the start of the study that do not worsen.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 66 of 90 Definition of SAE  
If an event is not an AE per definition above, then it cannot be a SAE even if serious conditions 
are met (eg, hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which the study 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
c. Requires inpatient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the study participant has been detained (usually involving at 
least an overnight stay) at the hospital  or emergency ward for observation and/or treatment that would 
not have been appropriate in the physician’s office or outpatient setting. Complications th at occur 
during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious 
criteria, the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, 
the AE should be considered serious.  
Hospitalization for elective treatment of a pre -existing condition that did not worsen from Baseline is 
not considered an AE.  
d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct n ormal life 
functions.  
• This definition is not intended to include experiences of relatively minor medical significance, 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
(eg, sprained ankle) which may interfere wit h or prevent everyday life functions but do not 
constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Important medical events:  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations, such as important medical events that may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the study  participant or 
may require medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually be considered serious.  
• Examples of such events include, but are not limited to, potential  Hy’s law, invasive or 
malignant cancers, intensive treatment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or 
development of drug dependency or drug abuse.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 67 of 90 Recording and follow -up of AE and/or SAE  
AE and SAE recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation (eg, hospital progress notes, laboratory reports, and diagnostics reports) related 
to the event.  
• The Investigat or will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptable for the Investigator to send photocopies of the study  participant’s medical 
records to UCB in lieu of completion of the UCB AE/SAE eCRF page.  
• There may be instances when copies of medical records for certain cases are requested by 
UCB. In this case, all participant identifiers, with the exception of the participant number, will 
be redacted on the copies of the medical records before submission to UCB.  
• The Investigator will  attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
Assessment of intensity  
The Investigator wi ll make an assessment of intensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories:   
• Mild: An event that is easily tolerated by the study  participant, causing minimal discomfort and 
not interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities.  
• Severe: An event that prevents normal everyday activities. An AE tha t is assessed as severe 
should not be confused with an SAE. Severe is a category utilized for rating the intensity of an 
event; and both AEs and SAEs can be assessed as severe.  
• An event is defined as “serious” when it meets at least 1 of the predefined out comes as 
described in the definition of a SAE, NOT when it is rated as severe (eg, a severe AE may be 
either serious or not serious, depending on whether these criteria are also met).  
The National Cancer Institute Common Terminology Criteria for Adverse Events should be used as a 
supportive standardization instrument to evaluate AEs and SAEs but the final intensity grading by the 
Investigator must be mild, moderate, or severe.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 68 of 90 Assessment of causality  
• The Investigator is obligated to assess the relation ship between study medication and each 
occurrence of each AE/SAE.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The In vestigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, 
as well as the temporal relationship of the event to study medication administration will b e 
considered and investigated.  
• The Investigator will also consult the IB and/or product information, for marketed products, in 
his/her assessment.  
• For each AE/SAE, the Investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in the initial report to UCB. Howev er, it is very important that the 
Investigator always make an assessment of causality for every event before the initial 
transmission of the SAE data to UCB.  
• The Investigator may change his/her opinion of causality in light of follow -up information and 
send an SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
 
Follow -up of AEs and SAEs  
• The Investigator is obligated to perform or arrange for t he conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by UCB to elucidate 
the nature and/or causality of the AE or SAE as fully as possible. This may include additional 
laboratory tests or investigations, histopa thological examinations, or consultation with other 
health care professionals.  
• An AE should be followed until it has resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically significant, or the study participant is lost to follow up. 
This follow -up requirement applies to AEs, SAEs, and AEs of special interest.  
• If a participant dies during participation in the study or during a recognized follow -up period, 
the Investigator will provide UCB with a copy of any post -mortem findings including 
histopathology.  
• New or updated information will be recorded in the originally completed eCRF.  
• The Investigator will submit any updated SAE data to UCB within 24 hours of receipt of the 
information.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 69 of 90 Reporting of SAEs  
SAE reporting to UCB  via an electronic data collection tool  
• The primary mechanism for reporting an SAE to UCB will be the electronic data collection 
tool. 
• If the electronic system is unavailable for more than 24 hours, then the site will use the paper 
SAE data collection too l (see next section).  
• The site will enter the SAE data into the electronic system as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken 
offline to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated data on a 
previously reported SAE after the electronic data collection tool has been taken offline, then 
the site can report this information on  a paper SAE form (see next section) or to the  UCB 
Study Physician/Medical Monitor by telephone.  
• Contacts for SAE reporting can be found in SERIOUS ADVERSE EVENT REPORTING . 
 
SAE reporting to UCB via paper CRF  
• Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the UCB Study Physician/Medical Monitor . 
• In rare circumstances and in the absence of facsimile equi pment, notification by telephone is 
acceptable with a copy of the SAE data collection tool sent by overnight mail or courier 
service.  
• Initial notification via telephone does not replace the need for the Investigator to complete and 
sign the SAE CRF pages w ithin the designated reporting time frames.  
• Contacts for SAE reporting can be found in SERIOUS ADVERSE EVENT REPORTING . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 70 of 90 10.4 Appendix 4: Contraceptive guidance and collection of 
pregnancy information  
Definitions  
Woman of childbearing potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below).  
Women in the following categories are not considered WOCBP : 
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
− Documented hysterectomy  
− Documented bilateral salpingectomy  
− Documented bil ateral oophorectomy  
Note: Documentation can come from the site personnel’s review of the study participant’s 
medical records, medical examination, or medical history interview.  
3. Postmenopausal female  
− A postmenopausal state is defined as no menses for 12 mon ths without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in  the absence of 
12 months of amenorrhea, a single FSH measurement is insufficient.  
− Females on HRT and whose menopausal status is in doubt will be required to use one of 
the nonestrogen hormonal highly effective contraception methods if they wish to 
continu e their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment.  
Contraception guidance  
Male participants  
For male participants with female partners of childbearing potential it is recommended that they 
agree to ONE of the following during the study and for at least 40  days after the last dose of 
study medication : 
• Are abstinent from penile -vaginal intercourse as their usual and preferred lifestyle (abstinent 
on a long -term and persistent basis) and agree to remain abstinent.  
• Agree to use a male condom when having penile -vaginal intercourse with a woman of 
childbearing potential who is not currently pregnant.  
In addition , male participants are recommended to refrain from donating sperm for the duration 
of the study and for 40 days after the last dose of study medication.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 71 of 90 Male participants with a pregnant or breastfeeding partner are recommended to remain abstinent 
from pe nile-vaginal intercourse or use a male condom during each episode of penile penetration 
during the study and for at least 40 days after the last dose of study medication.  
Female participants  
Female participants of childbearing potential are eligible to par ticipate if they agree to use a 
highly effective method of contraception consistently and correctly as described in  Table  10‒2, 
during the study and for at least 40  days after the last dose of study medication.  
Table  10‒2: Highly eff ective contraceptive methodsa 
Highly effective contraceptive methods that are user dependentb 
Failure rate of <1% per year when used consistently and correctly.  
Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of 
ovulation  
• Oral 
• Intravaginal  
• Transdermal  
Progestogen only hormonal contraception associated with inhibition of ovulation  
• Oral 
• Injectable  
Highly effective methods that are user independentc 
• Implantable progestogen only hormonal contraception  associated with inhibition of ovulation  
• IUD 
• IUS 
• Bilateral tubal occlusion  
Vasectomized partner  
Vasectomy is a highly effective contraception method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective 
method of contraception should be used.  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study medication. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of the participant.  
IMP=investigational medicinal product; IUD=intrauterin e device; IUS=intrauterine hormone -releasing system; 
WOCBP=woman of child -bearing potential  
a In case of newly started contraception pills/IUDs, the Investigator should consider the correct timing of 
starting/applying such methods in relation to the menstr ual cycle and the manufacturing instruction as to when 
these newly started methods would become effective.  
b Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with 
local regulations regarding the  use of contraceptive methods for participants participating in clinical studies.   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 72 of 90 Pregnancy testing  
• WOCBP should only be included after a confirmed menstrual period and a negative highly 
sensitive serum pregnancy test.  
• Additional pregnancy testing will be performed as described in the Schedule of Activities 
(Section  1.3). 
• Pregnancy testing will be performed whenever a menstrual cycle is missed or w hen 
pregnancy is otherwise suspected.  
• Pregnancy testing, with a sensitivity of 25mIU/mL will be performed.  
Male participants with partners who become pregnant  
• The Investigator will attempt to collect pregnancy information on any male participant’s 
female p artner who becomes pregnant while the male participant is in this study. This applies 
only to male participants who receive study medication.  
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the appropriate form and 
submit it to the Sponsor within 1  working day  of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. Information 
on the statu s of the mother and child will be forwarded to the Sponsor. Generally, the follow 
up will be at least 12 months after the delivery date. Any termination of the pregnancy will 
be reported regardless of fetal status (presence or absence of anomalies) or indi cation for the 
procedure.  
Female participants who become pregnant  
• Any female participant who becomes pregnant while participating in the study will be 
withdrawn from study medication . 
• The Investigator will collect pregnancy information on any female participant who becomes 
pregnant while participating in this study. Information will be recorded on the appropriate 
form and submitted to the Sponsor within 1 working day of learning of a participant's 
pregnancy. The participant will be followed to determi ne the outcome of the pregnancy. The 
Investigator will collect follow -up information on the participant and the neonate, and the 
information will be forwarded to the Sponsor. Generally, the follow up will be at least 
12 months after the delivery date. Any termination of pregnancy will be reported, regardless 
of fetal status (presence or absence of anomalies) or indication for the procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a p regnancy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be a SAE and will be reported as such. Any poststudy 
pregnancy -related SAE considered reasonably related to the study medication by the 
Investigator will be reported to the Sponsor as described in Section  8.3.5 . While the 
Investigator is not obligated to actively seek this information in former study participants , he 
or she may learn of an SAE through spontaneous reporting.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 73 of 90 10.5 Appendix 5: Genetics  
Not applicable.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 74 of 90 10.6 Appendix 6: Liver safety – suggested actions and follow -up 
assessments  
Study participants with PDILI must be assessed to determine if study medication must be 
discontinued. In addition, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued.  
Investigators should attempt to obtain information on study participants in the case of study 
medication disconti nuation to complete the final evaluation.  
Study participants with PDILI should not be withdrawn from the study until investigation and 
monitoring are complete. All results of these evaluations and observations, as well as the 
reason(s) for study medication  discontinuation and/or participant withdrawal (if applicable), 
must be recorded in the source documents. The eCRF must document the primary reason for 
discontinuation of study medication.  
A specific monitoring plan must be agreed between the UCB Study Phy sician and the 
Investigator for study participants who have ALT >5 ULN. The monitoring plan should include 
any necessary follow -up assessments (until resolution of the abnormal laboratory values).  
Phase 3 -4 liver chemistry stopping criteria are designed to  assure study participant safety and to 
evaluate liver event etiology.  
Liver chemistry stopping criteria and follow -up assessments are presented in  Table  10‒3. 
Table  10‒3: Liver chemistry stopping criteria and follow -up assessments  
Liver chemistry stopping criteria  
ALT -absolute  ALT 8x ULN  
ALT Increase  ALT 5xULN but <8xULN persists for 2 weeks  
ALT 3xULN but <5xULN persists for 4 weeks  
Bilirubina,b ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin)  
INRb ALT 3xULN and INR >1.5, if INR measured  
Cannot 
monitor  ALT 5xULN but <8xULN and cannot be monitored weekly for 2 weeks  
ALT 3xULN but <5xULN and cannot be monitored weekly for 4 weeks  
Symptomaticc ALT 3xULN associated with symptoms (new or worsening) believed to be related 
to liver injury or hypersensitivity  
Suggested actions and follow -up assessments  
Actions  Follow -up assessments  
• Immediately discontinue study medication  
• Report the event to UCB within  24 hours  
• Complete the liver event eCRF, and complete 
an SAE data collection tool if the event also 
met the criteria for an SAEb • Viral hepatitis serologyd 
• Obtain INR and recheck with each liver 
chemistry assessment until the 
transaminases values show downward trend  
• Only in those with underlying chronic 
hepatitis B at study entry (identified by 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 75 of 90 Table  10‒3: Liver chemistry stopping criteria and follow -up assessments  
Liver chemistry stopping criteria  
• Perform liver chemistry follow -up assessments  
• Monitor the participant until liver chemistry test 
abnormalities resolve, stabilize, or return to 
baseline (see MONITORING ) 
• Do not restart/rechallenge  participant with 
study medication unle ss allowed per protocol 
and UCB approval is granted  
• If restart/rechallenge is not allowed per 
protocol or not granted , permanently 
discontinue study medication, and continue 
participant in the study for any 
protocol -specified follow -up assessments  
• Consider  the need for a toxicology screening  
 
MONITORING:  
For bilirubin or INR criteria  
• Repeat liver chemistry tests (include ALT, 
AST, ALP, bilirubin)  and perform liver event 
follow -up assessments within 24 hours  
• Monitor participant twice weekly until liver 
chemi stry test abnormalities resolve, stabilize, 
or return to baseline  
• A specialist or hepatology consultation is 
recommended  
For all other criteria  
• Repeat liver chemistry tests (include ALT, 
AST, ALP, bilirubin) and perform liver 
chemistry follow -up assessment s within 24 to 
72 hours  
• Monitor participants weekly until liver 
chemistry abnormalities resolve, stabilize, or 
return to baseline  positive HBsAg): quantitative hepatitis B 
DNA and hepatitis delta antibodye 
• Obtain blood sample for PK analysis at the 
earliest time point following confirmation  of 
a liver eventf 
• Serum CPK and LDH  
• Fractionate bilirubin, if total bilirubin 
2xULN  
• Obtain complete blood count with 
differential to assess eosinophilia  
• Record the appearance or worsening of 
clinical symptoms of liver injury (eg, 
fatigue, nausea, vomiting, right upper 
quadrant pain), or hypersensitivity, on the 
AE eCRF  
• Record use of concomitant medications 
(including acetaminophen, herbal remedies, 
and other over -the-counter medications) on 
the concomitant medications eCRF.  
• Record alcohol use on th e liver event 
alcohol intake eCRF  
• Exclude pregnancy  
For bilirubin or INR criteria:  
• Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney 
microsomal antibodies, and quantitative 
total IgG or gamma globulins  
• Serum acetaminophen adduct HPLC assay 
(quantifies potential acetaminophen 
contribution to liver injury in participants 
with definite or likely acetaminophen use in 
the preceding week [James et al, 2009])  
NOTE: Not required in China  
• Liver imaging (ultrasound, magnetic 
resonance, or c omputerized tomography) 
and/or liver biopsy to evaluate liver disease; 
complete liver imaging and/or liver biopsy 
eCRFs  
AE=adverse event; ALP=alkaline phosphatase; ALT= alanine aminotransferase; AST=aspartate aminotransferase; 
CPK=creatine phosphokinase; eCRF=e lectronic case report form; HBsAg=hepatitis B surface antigen; 
HBcAb=hepatitis B core antibody; HPLC=high performance liquid chromatography; IgG=immunoglobulin G; 
IgM=immunoglobulin M; INR=international normalized ratio; LDH=lactate dehydrogenase; PC R=polymerase 
chain reaction; PK=pharmacokinetic; SAE=serious adverse event; ULN=upper limit of normal  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 76 of 90 Table  10‒3: Liver chemistry stopping criteria and follow -up assessments  
Liver chemistry stopping criteria  
a Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue st udy medication if ALT ≥3xULN and bilirubin ≥2xULN. Additionally, if 
serum bilirubin fractionation testing is unavailable, record the absence/presence of detectable urinary bilirubin 
on dipstick which is indicative of direct bilirubin elevations suggesting liver injury.  
b All events of ALT ≥3xULN and bilirubin ≥2xULN (>35% direct bilirubin) or ALT ≥3xULN and INR >1.5 may 
indicate severe liver injury (possible ‘Hy’s Law’) and must be reported as an SAE (excluding studies of hepatic 
impairment or cirrhosis). T he INR measurement is not required and the stated threshold value will not apply to 
participants receiving anticoagulants.  
c New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right 
upper quadrant pain or t enderness, or jaundice) or hypersensitivity (such as fever, rash or eosinophilia).  
d Includes: Hepatitis A IgM antibody; HBsAg and HBcAb; hepatitis C RNA; cytomegalovirus IgM antibody; 
Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, hete rophile antibody or monospot testing); 
and hepatitis E IgM antibody.  
e If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis delta RNA 
virus (where needed) (Le Gal et al, 2005) . 
f Record the date/time of the PK b lood sample draw and the date/time of the dose of study medication prior to the 
PK blood sample draw on the eCRF. If the date or time of the last dose is unclear, provide the participant’s best 
approximation. If the date/time of the last dose cannot be app roximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shipping are 
in the Laboratory Manual . 
Liver chemistry increased monitoring criteria with continued study medication are presented in  
Table  10‒4. 
Table  10‒4: Liver chemistry  increased monitoring criteria with continued study 
medication  
Liver chemistry increased monitoring criteria  
Criteria  Actions  
ALT 5xULN and  <8xULN and bilirubin 
<2xULN without  symptoms believed to 
be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 2  weeks.  
OR 
ALT 3xULN and <5xULN and bilirubin 
<2xULN without  symptoms believed to 
be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 4  weeks.  • Notify the UCB Medical Monitor within 24  hours  of 
learning of the abnormality to discuss participant 
safety.  
• Participant can continue study medication . 
• Participant must return weekly for repeat liver 
chemistry tests (ALT, AST, ALP, bilirubin) until the 
abnormalities resolve, stabilize, or return to baseline.  
• If at any time, the participant meets liver chemistry 
stopping criteria, proceed as described in 
Section  7.1.1 . 
• If ALT decreases from ALT 5xULN and  <8xULN to 
≥3xULN but <5xULN, continue to monitor liver 
chemistries weekly.  
• If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor participants twice monthly 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 77 of 90 Table  10‒4: Liver chemistry  increased monitoring criteria with continued study 
medication  
Liver chemistry increased monitoring criteria  
until liver chemistry tests resolve, stabilize, or return 
to baseline.  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit 
of normal  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 78 of 90 10.7 Appendix 7: Medical device AEs, adverse device effects, SAEs, 
and device deficiencies: Definition and procedures for 
recording, evaluating, f ollow -up, and reporting  
Not applicable.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 79 of 90 10.8 Appendix 8: Rapid alert procedures  
Not applicable.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 80 of 90 10.9 Appendix 9: Country -specific requirements  
Not applicable.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 81 of 90 10.10  Appendix 10: Abbreviations and trademarks  
AE adverse event  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
BMI  body mass index  
C5 complement component 5  
CFB  change from Baseline  
COVID -19 coronavirus disease 2019  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CV coefficient of variation  
ECG  electrocardiogram  
eCRF  electronic case report form  
ES Enrolled Set  
EW Early Withdrawal  
FSH follicle stimulating hormone  
GCP  Good Clinical Practice  
gMG  generalized myasthenia gravis  
HRT  hormonal replacement therapy  
IB Investigator’s Brochure  
ICF Informed Consent form  
ICH International Council for Harmonisation  
IMP Investigational Medicinal Product  
IRB Institutional Review Board  
IST immunosuppressant therapy  
ITT Intention -to-Treat  
IV intravenous  
IVIG  intravenous immunoglobulin G  
MG myasthenia gravis  
MG-ADL  Myasthenia Gravis -Activities of Daily Living  
MGC  Myasthenia Gravis Composite  
MGFA  Myasthenia Gravis Foundation of America  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 82 of 90 MG-QOL15r  Myasthenia Gravis -Quality of Life Revised  
mITT  Modified Intention -to-Treat  
NI noninferiority  
PD pharmacodynamic(s)  
PDILI  potential drug -induced liver injury  
PD-PPS Pharmacodynamic Per -Protocol Set  
PK pharmacokinetic(s)  
PK-PPS Pharmacokinetic Per -Protocol Set  
PLEX  plasma exchange  
PRO  patient -reported outcome  
QMG  Quantitative Myasthenia Gravis  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SC subcutaneous(ly)  
SD standard deviation  
SFU Safety Follow -up 
SOC  standard of care  
SOP standard operating procedure  
SS Safety Set  
TEAE  treatment -emergent adverse event  
TSQM -9 9-item Treatment Satisfaction Questionnaire for Medication  
ULN  upper limit of normal  
WOCBP  woman of childbearing potential  
ZLP zilucoplan  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 83 of 90 10.11  Appendix 11: Protocol amendment history  
Amendment 1 (15 Jul 2022)  
Overall Rationale for the Amendment:  
The protocol amendment was considered necessary to remove the requirement for the collection 
of blood samples for exploratory biomarkers, and to add that back -up samples may be retained 
for future exploratory biomarker analysis. Additional changes include the following: clarified 
that screening clinical laboratory and physical examination assessments will be considered the 
baseline values for evaluating the other safety endpoints; removed the requirement for brief 
physical examinations, and electronic versi on of the C -SSRS scale; and amended the 
contraception guidance. The table below does not include correction of minor typographical 
errors and formatting/stylistic changes.  
Section # and Name  Description of Change  Brief Rationale  
Section 1.1, Synopsis, 
Table  1-1 -Added ECG to other safety endpoints   
 
-Added footnote “a” to clarify that the 
clinical laboratory, physical 
examination, and ECG assessments 
conducted at screening will be 
considered the baseline values for 
evaluating the other safety endpoints.  -Added for the evaluation of 
updated corrected QT 
interval (QTc) stopping 
criteria  
-As clinical laboratory, 
physical examination, and 
ECG assessments are not 
performed at the Baseline 
Visit in this study, footnote 
“a” was added to clarify and 
confirm that  the respective 
screening assessments will be 
considered as baseline when 
evaluating the other safety 
endpoints.  
Section 1.3, Schedule of 
Activities, Table 1 -2 -Removed brief physical examination 
and footnote “n”, regarding brief 
physical examination at t he Baseline 
Visit.  -Removed in order to have a 
consistent approach to all 
study participants, and to 
reduce study complexity and 
patient burden.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 84 of 90 Section # and Name  Description of Change  Brief Rationale  
Section 1.3, Schedule of 
Activities, Table 1 -2 -Removed requirement for blood 
sampling for exploratory biomark er 
analyses.  
-Added to footnote “u” that back -up 
specimens may be retained for future 
exploratory biomarker analyses.  
 
 
 
-Added ECG assessment to Screening 
Visit, at Week 2, Week 12, Early 
Withdrawal, and Safety Follow -up 
visits.  
 
 
 
-Remove footnote “n” saying that vital 
signs will be assessed at all complete 
and brief physical examination.  
 
 
-Added footnote “n” to specify that 
clinical laboratory, physical 
examination, and ECG assessments 
conducted at Screening will be 
considered the baseline values for 
evaluating of the other safety endpoints.  
 -Collection of additional 
specimens is no longer 
necessary because the 
exploratory biomarker 
specimen analyses could be 
performed with the existing 
back -up specimens, which 
are collected as part of the 
pharmacokin etic/ 
pharmacodynamic analyses.  
-ECG added to evaluate QTc 
criteria to determine 
eligibility (see exclusion 
criteria #11) and added to 
safety assessments to 
evaluate QTc stopping 
criteria.  
-Timepoints for vital signs 
evaluations are shown in 
Table 1 -2 and there is need to 
add a footnote to specify 
these timepoints.  
-As clinical laboratory, 
physical examination, and 
ECG assessments are not 
performed at the Baseline 
Visit in this study, footnote 
“n” was added to clarify and 
confirm that the respective 
screeni ng assessments will be 
considered as baseline when 
evaluating the other safety 
endpoints.  
Section 3, Table 3 -1 -Added ECG to other safety endpoints.   
 
-Added footnote “a” to clarify that the 
clinical laboratory, physical 
examination, and ECG assessments 
conducted at screening will be 
considered the baseline values for 
evaluating the other safety endpoints.  -Added for the evaluation of 
updated QTc stopping 
criteria.  
-As clinical laboratory, 
physical examination, and 
ECG assessments are not 
performed at the Baseline 
Visit in this study, footnote 
“a” was added to clarify and 
confirm that the respective 
screening assessments will be 
considered as baseline when 
evaluating the other safety 
endpoints.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 85 of 90 Section # and Name  Description of Change  Brief Rationale  
Section 5.2 Exclusion 
criteria  The following exclusion criteria #11 
was added:  
QTc interval >450msec for male 
participants, QTc >470msec for female 
participants, or QTc >480 msec in 
participants with bundle branch block.  
NOTE: The QTc is the QT interval 
corrected for heart rate according to 
Fridericia's formul a (QTcF). It is either 
machine read or manually overread.  QTc should serve as a criteria 
to determine eligibility for an 
individual participant prior to 
initiation of the study.  
Section 6.1 Treatments 
administered  Changed treatment type from 
“Biologic” t o “Drug” in Table 6 -1 
Treatment administered.  Correction of classification 
error.  
Section 7.1.2 QTc stopping 
criteria  Updated QTc stopping criteria.  QTc stopping criteria updated 
to provide more specific 
stopping criteria.  
Section 8.1.2, 
Pharmacodynamics  
Section 8.6, 
Pharmacokinetics  Added that back -up samples already 
planned for collection will be stored for 
all participants in this study to support 
potential future exploratory biomarker 
research.  The addition of the text is 
to clarify that the collected  
samples for PK and PD 
can be used for future 
exploratory analysis as the 
stand -alone exploratory 
biomarker samples have 
been removed from the 
schedule of assessments.  
Section 8.2.3, 
Electrocardiogram  ECG added to safety assessments.  ECGs added to safety 
assessments to measure PR, 
QRS, QT, and QTc intervals.  
Section 8.2.5, Suicidal risk 
monitoring  -Removed statement that an electronic 
version of the C -SSRS scale will be 
used for screening as well as to assess 
suicidal ideation and behavior that may 
occur during the study.  
-Corrected that the 
“Screening/Baseline” version of the C -
SSRS should only be used at the 
Screening Visit and not anymore at the 
Baseline Visit, and that the “Since Last 
Visit” version should be used at all 
other timepoints, including at the 
Baseline Visit.  
 
 
 -An electronic version of the 
C-SSRS scale will not be 
used in this study.  
 
 
 
-The Screening/Baseline 
version of the C -SSRS 
should only be used at the 
Screening Visit and not 
anymore at the Baseline 
Visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 86 of 90 Section # and Name  Description of Change  Brief Rationale  
Section 8.7, Biomarkers  Removed requirement for blood 
sampling for exploratory biomarker 
analyses.  Collection of additional 
specimens is no longer 
necessary because the 
exploratory biomarker 
specimen analyses could be 
performed with the existing 
back -up specimens, which 
are collect ed as part of the 
pharmacokinetic/  
pharmacodynamic analyses.  
Section 9.4.1, Safety 
analyses  Added to clarify that ECG will also be 
presented in listings and summarized 
over time.  
Added to clarify that the clinical 
laboratory, physical examination, and 
ECG  assessments conducted at 
screening will be considered as baseline 
values for the assessment of the other 
safety endpoints.  As clinical laboratory, 
physical examination, and 
ECG assessments are not 
performed at the Baseline 
Visit in this study, text was 
added to clarify and confirm 
that the respective screening 
assessments will be 
considered as baseline when 
assessing the other safety 
endpoints.   
Section 10.4, Appendix 4: 
Contraceptive guidance and 
collection of pregnancy 
information, Table 10 -2 Removed fo otnote “c” regarding 
hormonal contraception.   No drug -drug interactions are 
expected; therefore, footnote 
“c” was removed in order to 
streamline the contraceptive 
guidance and to avoid any 
confusion.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 87 of 90 Amendment 2 (21 Oct 2022)  
Overall Rationale for the Amendment:  
The protocol amendment was considered necessary to remove the SAE reporting requirement 
from the C -SSRS assessment for a positive response to Question 4. The question asks whether 
the participant has had suicidal thoughts or ideations since the last visit. Adverse event or SAE 
reporting following C -SSRS assessment should follow the standard processes as described in 
Section 8.3 and Section 10.3.  
Additional changes include defining the number of missed doses that constitutes a major 
protocol devia tion and clarifying that the withholding of cholinesterase inhibitors for 10 hours is 
required only prior to the QMG assessment and not prior to the MG -ADL administration. The 
table below does not include correction of minor typographical errors and format ting/stylistic 
changes.  
Section # and Name  Description of Change  Brief Rationale  
Section 6.4, Treatment 
Compliance  Added statement that if a participant 
misses 10 or more consecutive doses, 
he/she must notify the investigator 
immediately, the medical monitor 
should be consulted, and this will be 
considered a major protocol deviation.  To define the threshold of 
missed doses that will require 
review by the medical 
monitor and recording of a 
major protocol deviation.  
Section 6.5.1, Permitted 
concomitant  treatments 
(medications and therapies)  Clarified that withholding of 
cholinesterase inhibitors 10 hours prior 
applies to QMG (not required for 
MG-ADL assessment).  Withholding of 
cholinesterase inhibitors is a 
requirement for QMG, not 
for MG -ADL.  
Section  8.1.1.1,  MG-ADL  Removed requirement for withholding 
cholinesterase inhibitors 10 hours prior 
to MG -ADL assessment.  Considering the 7 days recall 
period for answering the 
questions, withholding of 
cholinesterase inhibitors is 
not a requirement for MG -
ADL.  
Section 8.2.5, Suicidal risk 
monitoring  Added statement that families and 
caregivers should be instructed to 
monitor participants for/ report 
emergence of unusual changes in 
behavior or emergence of suicidal 
ideation and behavior.  
Removed statement that a  positive 
response to question 4 on the “since last 
visit” C -SSRS must be reported to UCB 
via the SAE process.  Removal of ambiguous 
wording specific to C -SSRS 
Question 4 and clarification 
of the role of caregivers in 
family in reporting changes 
in behavior . Adverse events 
or SAEs reporting following 
C-SSRS assessment should 
follow the standard processes 
as described in Section 8.3 
and Section10.3.  
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 88 of 90 11 REFERENCES  
Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment 
satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy 
consumers. Value Health. 2005;8 Suppl 1:S9 -24. 
Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, 
the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study 
of chronic disease. Health Qual Life Outcomes. 2004;2(1):12.  
Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the 
quantitative myasthenia gravis score . Ann N Y Acad Sci. 1998:841:769 -72. 
Benatar M, Sanders DB, Burns TM, et al. Recommendations for myasthenia gravis clinical trials. 
Muscle Nerve. 2012;45(6):909 -17. 
Bharmal M, Payne K, Atkinson MJ, Desrosiers M -P, Morisky DE, Gemmen E. Validation of an 
abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM -9) among patients on 
antihypertensive medications. Health Qual Life Outcomes. 2009;7(1):36.  
Burns TM, Grouse CK, Conaway MR, Sanders DB; mg composite and mg -qol15 study group. 
Construct and  concurrent validation of the MG -QOL15 in the practice setting. Muscle Nerve. 
2010;41(2):219 -26. 
Burns TM, Sadjadi R, Utsugisawa K, et al. International clinimetric evaluation of the 
MG-QOL15, resulting in slight revision and subsequent validation of the MG‐QOL15r. Muscle 
Nerve. 2016;54(6):1015 -22. 
Chamanza R, Marxfeld HA, Blanco AI, Naylor SW, Bradley AE. Incidences and range of 
spontaneous findings in control cynomolgus monkeys (Macaca fascicularis) used in toxicity 
studies. Toxicol Pathol. 2010;38(4):642 -57. 
Food and Drug Administration. Guidance for Industry. Suicidal ideation and behavior: 
prospective assessment of occurrence in clinical trials. US Dept of Health and Human Services, 
Center for Drug Evaluation and Research, 08/2012. Availab le upon request.  
Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570 -81. 
Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic 
strategies. Lancet Neurol. 2015;14(10):1023 -36. 
Howard JF Jr. Myasthenia gravis: the ro le of complement at the neuromuscular junction. Ann N 
Y Acad Sci. 2018;1412(1):113 -28. 
Howard JF Jr, Nowak RJ, Wolfe GI, et al. Clinical effects of the self -administered subcutaneous 
complement inhibitor zilucoplan in patients with moderate to severe gener alized myasthenia 
gravis. Results of a Phase 2 randomized, double -blind, placebo -controlled, multicenter clinical 
trial. JAMA Neurol. 2020;77(5):582 -592. 
Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double -blind, placebo -controlled 
phase II stu dy of eculizumab in patients with refractory generalized myasthenia gravis. Muscle 
Nerve. 2013;48(1):76 -84. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 89 of 90 Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in 
anti-acetylcholine receptor antibody -positive refractory generali sed myasthenia gravis 
(REGAIN): a phase 3, randomised, double -blind, placebo -controlled, multicentre study. Lancet 
Neurol. 2017;16(12):976 -86. 
James LP, Letzig L, Simpson PM, et al. Pharmacokinetics of acetaminophen -protein adducts in 
adults with acetamino phen overdose and acute liver failure. Drug Metab Dispos. 
2009;37:1779 -84. 
Katzberg HD, Barnett C, Merkies ISJ, Bril V. Minimal clinically important difference in 
myasthenia gravis: outcomes from a randomized trial. Muscle Nerve. 2014;49(5):661 -5. 
Le Gal F , Gordien E, Affolabi D, et al. Quantification of hepatitis delta virus RNA in serum by 
consensus real -time PCR indicates different patterns of virological response to interferon therapy 
in chronically infected patients. J Clin Microbiol. 2005;43(5):2363 -9. 
Mundt JC, Greist JH, Gelenberg AJ, et al. Feasibility and Validation of a Computer -Automated 
Columbia -Suicide severity Rating Scale Using Interactive Voice Response Technology. J 
Psychiatr Res. 2010;44(16):1224 -8. 
Muppidi S, Wolfe GI, Conaway M, Burns TM . MG -ADL: still a relevant outcome measure. 
Muscle Nerve. 2011;44(5):727 -31. 
Posner K, Brown GK, Stanley B, et al. The Columbia -Suicide Severity Rating Scale: initial 
validity and internal consistency findings from three multisite studies with adolescents and 
adults. Am J Psychiatry. 2011;168(12):1266 -77. 
Ramizuddi MK. Review on: Myasthenia gravis and telithromycin -myasthenia crisis. IOSR J 
Dent Med Sci. 2014;13(7):67 -97. 
Regnault A, Balp MM, Kulich K, Viala -Danten M. Validation of the Treatment Satisfactio n 
Questionnaire for Medication in patients with cystic fibrosis. J Cyst Fibros. 2012;11(6):494 -501. 
Sadjadi R, Conaway M, Cutter G, Sanders DB, Burns TM. MG Composite and MG -QOL15 
Study Group. Pyschometric evaluation of the myasthenia gravis composite usin g Rasch analysis. 
Muscle nerve. 2012;45(6):820 -5. 
Vaccine Recommendations and Guidelines of the ACIP. Centers for Disease Control and 
Prevention.  https://www.cdc.gov/vaccines/hcp/acip -recs/index.html  
Vissing J, Jacob S, Fujita KP, et al. ‘Minimal symptom e xpression’ in patients with acetylcholine 
receptor antibody -positive refractory generalized myasthenia gravis treated with eculizumab. 
J Neurol. 2020;267(7):1991 –2001.  
Vu T, Meisel A, Mantegazza R, et al. Terminal Complement Inhibitor Ravulizumab in 
Genera lized Myasthenia Gravis. NEJM Evidence. 2022; 1(5).  
Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis 
activities of daily living profile. Neurology. 1999;52(7):1487 -9. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   30 Nov 2022  
Clinical Study Protocol Amendment 3  Zilucoplan  MG0017  
   
Confidential  Page 90 of 90 SPONSOR DECLARATION  
I confirm that I have carefully rea d and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
Approval Signatures
Name: mg0017-protocol-amend-3-30Nov2022
Version: 2 . 0
Document Number: CLIN-000207750
Title: mg0017 protocol amendment 3 30 Nov 2022
Approved Date: 30 Nov 2022
Document Approvals
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 30-Nov-2022 14:29:26 GMT+0000
Approval
Verdict: ApprovedName: 
Capacity: Subject Matter Expert
Date of Signature: 30-Nov-2022 14:36:41 GMT+0000
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 30-Nov-2022 15:59:11 GMT+0000
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 